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Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy 
mainly due to lack of specific symptoms and effective screening methods that allow 
an early detection. It is also a very heterogeneous disease with various histological 
subtypes and classification criteria. Epithelial ovarian carcinomas from carriers of 
BRCA1 and BRCA2 mutations present distinct clinical and histopathological features 
when compared to sporadic tumors. In particular, it has been shown that BRCA1/2 
carriers respond better to standard therapy, show improved survival and are likely to 
respond to PARP inhibition. However, few studies have attempted to characterize 
genomic changes occurring in hereditary EOC and inconsistent results have been 
obtained. In addition, due to just a short-term survival benefits achieved by current 
treatment of advanced cases another priority in the field is to develop better 
prognostic and/or predictive markers that help to improve patients’ outcome and to 
improve quality of life.  
 
With these antecedents, in this study we aimed to characterize the profile of 
genomic alterations in hereditary and sporadic ovarian tumors and to assess the 
usefulness of DNA copy number changes, as potential prognostic and predictive 
biomarkers. 
 
To address this we conducted a high-resolution array-based Comparative 
Genomic Hybridization (aCGH) profiling of 53 familial and 15 sporadic paraffin-
embedded EOCs. We also integrated this data with immunohistopathological and 
clinical features in order to define potential common and subtype-specific features 
and to identify DNA copy number changes associated with survival or other 
biologically relevant characteristics. Three additional datasets consisting of 103 EOCs 
characterized by FISH, 411 high-grade serous ovarian carcinomas (HGSOCs) from 
TCGA and 1436 EOCs from the KM-plotter, in-silico tool, were used for validation of 
potential biomarkers. 
 
Our results indicate that a high level of genomic instability and a greater 
contribution of losses versus gains are a common feature in EOC. We also found that 
sporadic and familiar EOC exhibit a similar global pattern of DNA copy number 
changes and that groups of EOC defined based on their DNA copy number profiles 
Abstract 
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show an association with histotype, FIGO stage and proliferation-related markers 
rather than with their familiar or sporadic condition. We identified common, 
recurrently altered regions in hereditary and sporadic tumors that would encompass 
genes potentially fundamental for ovarian carcinogenesis, independently from 
BRCA1/2 mutations. Importantly, despite global similarity between sporadic and 
hereditary EOC we found that extensive genomic loss was significantly higher in 
tumors from BRCA1 and BRCA2 mutation carriers making this feature potentially 
clinically relevant in guiding the selection of BRCA-related patients, who are likely to 
respond to PARP inhibitors. Finally, integration of immunohistopathological and 
clinical data led us to demonstrate at the DNA copy-number level in 563 tumors and 
at the gene expression level in 1436 EOC that the 6q24-26 deletion is an independent 
marker of favorable outcome in ovarian cancer. In particular, our results indicate 
prognostic utility in HGSOCs, the most common and aggressive EOC subtype. This 
finding has a potential clinical value as the deletion can be analyzed by FISH and 
guide patients´ selection towards more conservative therapeutic strategies to reduce 
side-effects and improve quality of life.  
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El cáncer epitelial de ovario es la neoplasia ginecológica más letal 
principalmente debido a la ausencia de síntomas específicos y a la falta de métodos de 
cribado efectivos que permitan una detección precoz. Se trata de una enfermedad 
muy heterogénea con numerosos subtipos histológicos y diferentes criterios de 
clasificación. Los carcinomas epiteliales de ovario (CEO) de pacientes portadoras de 
mutaciones en los genes BRCA1 y BRCA2 presentan unas características clínicas e 
histopatológicas distintivas. En concreto se ha demostrado que las portadoras de 
dichas mutaciones responden mejor a la quimioterapia convencional, presentan 
mejores supervivencias y tienden a responder al tratamiento con inhibidores de 
PARP. Sin embargo en muy pocos estudios se ha abordado la caracterización de los 
cambios genómicos que tienen lugar en los CEO hereditarios y estos han producido 
resultados contradictorios. Por otra parte los tratamientos estándar actuales ofrecen 
pobres perspectivas de supervivencia  a las pacientes con tumores diseminados. Por 
ello, otra prioridad en  este campo es el desarrollo de mejores marcadores 
pronósticos y predictivos que permitan mejorar la expectativa y calidad de vida de las 
pacientes.  
 
Con estos antecedentes en el presente estudio hemos abordado la 
caracterización del patrón de cambios genómicos de los tumores de ovario familiares 
y esporádicos. Asimismo hemos evaluado los cambios en el número de copias de ADN 
como potenciales biomarcadores pronósticos y predictivos.  
 
Para ello hemos analizado mediante Hibridación Genómica Comparativa en 
soporte de array (aCGH)  53 tumores de ovario familiares y 15 tumores de ovario 
esporádicos, todos ellos embebidos en parafina.  Hemos integrado los resultados 
derivados de dicho análisis con datos inmunohistopatológicos y clínicos para definir 
alteraciones potencialmente comunes y específicas de los distintos grupos tumorales 
y para  identificar cambios en el número de copias de ADN asociados con 
supervivencia u otras características biológicamente relevantes. Con el objeto de 
validar posibles biomarcadores candidatos se han usado tres series adicionales de 
tumores consistentes en 103 CEO caracterizados mediante FISH, 411 carcinomas 
serosos de alto grado del estudio del TCGA  y 1436 CEO recogidos en la herramienta 
in-silico KM-plotter.  
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Nuestros resultados señalan que la alta inestabilidad genómica y la mayor 
contribución de las pérdidas en relación con las ganancias serían rasgos 
característicos de los CEO. También hemos constatado que los CEO familiares y 
esporádicos exhibirían un patrón similar de cambios en el número de copias de ADN 
y que grupos de tumores definidos en función de dichas alteraciones se asociarían 
con el subtipo histológico, el estadio FIGO y marcadores de proliferación y no con  su 
origen esporádico o hereditario.  Hemos identificado  alteraciones recurrentes 
comunes a ambos tipos de tumores que contendrían genes potencialmente 
importantes para la patogénesis de cáncer de ovario independientemente de la 
existencia de mutaciones en los genes BRCA1 y BRCA2. Cabe resaltar que a pesar de la 
similitud global entre los CEO hereditarios y esporádicos hemos observado  que las 
pérdidas genómicas serían particularmente acusadas en los tumores de portadoras 
de mutaciones en BRCA1 y BRCA2. Esta característica podría tener relevancia clínica 
en la selección de pacientes “BRCA-like” para las cuales se han descrito buenas 
respuestas a tratamientos con inhibidores de PARP. Por último, la integración de 
datos immunohistopatológicos y clínicos nos ha permitido demostrar en 563 CEO a 
nivel de cambios en el número de copias de ADN y en 1436 CEO a nivel de expresión 
génica que la deleción en 6q24-26 sería un marcador independiente de pronóstico 
favorable en cáncer de ovario. En concreto nuestros resultados señalan valor 
pronóstico en los tumores serosos de alto grado que constituyen el subtipo más 
común y agresivo. Este hallazgo presentaría una potencial aplicación clínica ya que 
mediante la determinación de la deleción con FISH se podrían seleccionar pacientes 
susceptibles de beneficiarse de estrategias terapéuticas más conservadoras que 
presentan menores efectos secundarios y repercusión en la calidad de vida.  
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1 OVARIAN CANCER  
 
Ovaries are female reproductive organs located on either side of the uterus below the 
fallopian tubes and responsible for hormone secretion and more importantly for housing and 
releasing oocytes or eggs (germ cells), which are essential for reproduction (Rosai, 2004) 
(Figure 1A). 
 
The ovary is covered by a single layer called the ovarian surface epithelium (SE). The 
ovarian stroma is divided into an outer-cortical and inner medullar sections, but the 
bounders between them are indistinct. The cortex is where the follicles and oocytes are found 
at various stages of development and degeneration and is made of tightly packed connective 
tissue. The medulla is where the ovarian vasculature is found and is primarily loose stromal 
tissue (Rosai, 2004) (Figure 1B). 
 
Different ovarian tumors are classified on the basis of their cell or tissue of origin. 
Approximately 90% of all ovarian cancers are epithelial and the other 10% are made up by 
gonadal-stromal (6% occurrence) and germ cell (4% occurrence) tumors (Holschneider & 
Berek, 2000). Ovarian cancer of epithelial cell origin is the most common type and it will be 
the focus of this study.  
 
  
 
Figure 1. Structure of the gynecological track (A) and the cross section of ovary (B) SE, surface epithelium;  
O, oocyt (www.accessmedicine.com) 
V  
A  
B 
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2 EPITHELIAL OVARIAN CANCER (EOC)  
 
2.1 EPIDEMIOLOGY  
 
Ovarian cancer is the seventh most common and most deadly cancer worldwide. 
Among gynecological malignancies it is the second most common (after cervical cancer) and 
first cause of cancer-related deaths (Ferlay J et al, 2013). 
 
The lifetime risk of ovarian cancer is 0.67%, meaning that one in 149 women will 
develop the cancer in the general population by the age of 74. However the risk varies 
significantly worldwide with higher rates observed in more developed countries (1.01%) 
reaching the highest in Central and Eastern Europe (1.25%; 1 in 80 women) and lowest in the 
third world countries (0.43%) (Ferlay J et al, 2013). 
 
The age-standarized worldwide incidence rate (ASR) is 6 per 100,000 women per 
year, and it is higher for Caucasian, than for African and Asian women (Ferlay J et al, 2013) 
(Figure 2). 
 
 
 
Figure 2. Estimated age-standarized incidence rate of ovarian cancer per 100,000 women (Globocan 2012) 
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 Spain occupies an intermediate position worldwide, with ASR of 8 cases and 
mortality rate of 4 cases per 100.000 women per year, placing Spain on fifth position with the 
lowest mortality rate of this cancer in Europe (Ferlay J et al, 2013). 
 
In ovarian cancer incidence is strongly related to age, with the highest rates being in 
older women. The largest number of patients with epithelial ovarian cancer is found in the 
60–64 years old women (Berek et al, 2012). 
 
 
2.2  CLASSIFICATION OF EOC 
2.2.1  Histological subtypes 
 
Epithelial ovarian canner is subdivided into benign, borderline (intermediate) and 
malignant (carcinomas) depending on the degree of cell proliferation, nuclear atypia, and the 
presence or absence of stromal invasion.  About 10% of epithelial ovarian neoplasms are 
borderline tumors that show higher (than in benign counterparts) degree of cellular 
proliferation and variable nuclear atypia in the absence of stromal invasion. Despite the lack 
of stromal invasion they can progress to low grade serous carcinomas (LGSOCs) and invade 
underlying tissues (Prat, 2012b). 
 
The malignant epithelial tumors (carcinomas) account for the majority of EOC (90% 
of cases) (Prat, 2012a). Initially they were considered as a single entity, however currently on 
the basis of their immunohistopathological and molecular features they are classified into 
five main subtypes:  high-grade serous carcinomas (HGSCs) (70%), endometrioid carcinomas 
(ECs) (10%), clear cell carcinomas (CCCs) (10%), mucinous carcinomas (MCs) (3 %), and low 
grade serous carcinomas LGSOCs (<5%) (Prat, 2012b). Other less common types are Brenner, 
small cell, mixed and undifferentiated carcinomas.  
 
2.2.2  Type I and Type II tumors 
 
Besides the standard stratification of the EOC based on histopathological and 
immunohistochemical characteristics a more recent dualistic model categorizes various types 
of ovarian cancer into two designated types:  type I and type II (Shih Ie & Kurman, 2004). 
Type I tumors are considered as clinically indolent, diagnosed at early stages and are 
Introduction  
 
Page | 40  
 
represented by low-grade serous, low-grade endometrioid, clear cell, and mucinous subtype. 
They grow slowly and develop in a stepwise manner from well-recognized precursors, 
namely borderline tumors. In contrast, type II tumors are usually highly aggressive, present 
at higher stage and are diagnosed as high-grade serous, high-grade endometrioid or 
undifferentiated carcinomas. They are rarely associated with morphologically recognizable 
precursor lesions and evolve rapidly, metastasizing early in their course. They account for 
approximately 75% of all epithelial ovarian carcinomas, show greater genomic instability, 
molecular homogeneity and have a uniformly poor outcome (Kurman & Shih Ie, 2010).  
 
The morphologic differences between both tumor types are reflected substantially 
by distinct molecular features (Cho & Shih Ie, 2009). Type I tumors are more genetically 
stable and display wide range of mutations specific for each histological type (Kuo et al, 
2009). Thus, KRAS, BRAF, and ERBB2 mutations are characteristic for majority (75%) of low-
grade serous carcinomas, while aberrations in the Wnt signaling pathway involving somatic 
mutations of CTNNB1 (encoding β-catenin), PTEN and PIK3CA are specific for low-grade 
endometrioid carcinomas. Mucinous tumors present KRAS mutations in more than half of the 
cases, while clear cell carcinomas show a high percentage of PIK3CA activating mutations 
(Kurman & Shih Ie, 2010). The prototypic type II tumors, high-grade serous carcinomas, are 
characterized by very frequent TP53 mutations (>80% of cases) and CCNE1 amplification, but 
rarely present the mutations found in type I tumors (Cho & Shih Ie, 2009). 
 
 
2.3  CLINICAL MANAGEMENT OF EOC   
 
Cancer staging and grading are used to predict the clinical behavior of malignancies, 
establish appropriate therapies, and facilitate exchange of precise information between 
clinicians. During the staging/grading process, patients are placed in standardized categories 
according to the anatomical location of dissemination and the pathologic characteristics of 
their tumors. 
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2.3.1  Ovarian cancer staging and grading  
 
The extent of tumoral spread, also known as stage of disease, at diagnosis is typically 
established by radiological evaluation and surgical excision and it is essential for determining 
the correct treatment strategy for an individual patient. 
 
Currently used staging system published in Twenty-sixth Volume of the FIGO 
(International Federation of Gynecology and Obstetrics) Annual Report unifies tumor-node-
metastasis (TNM) and FIGO classification (Heintz et al, 2006). TNM system determinates the 
extent of the tumor spread, assigning “T” if it is only confined to the ovary and nearby organs, 
“N” if involves lymph nodes, or “M” if already affects distant organs (Fleming et al, 1997). 
Staging according to FIGO guidelines defines 4 stages: Stage I reflecting the tumor that is 
strictly confined to the organ of origin; Stage II - tumor extended  beyond the site of origin 
involving local adjacent organs or structures; Stage III - more extensive tumor involvement, 
i.e., wide infiltration reaching neighboring organs; and Stage IV - clearly distant metastasis 
(Heintz et al, 2001). Those basic stages are then classified into substages, as a reflection of 
specific clinical, pathological, or biological prognostic factors within a given stage.  
 
In addition, several grading systems are used for ovarian carcinoma, however most 
of them are based on analyzes of histologic type, architectural pattern, nuclear/cytologic 
atypia, mitotic index, or a combination of these features.  
 
Currently there are two commonly used grading systems: the universal grading 
system proposed by Shimizu-Silverberg (Silverberg, 2000) and the two-tier for serous 
carcinomas defined by M. D. Anderson 
Cancer Center (MDACC) (Malpica et al, 
2004). 
 The 3-tier Shimizu-
Silverberg classification is based on 
the Nottingham system for breast 
carcinomas and uses three 
parameters:  architectural pattern 
Table1. Proposed universal grading system for invasive 
ovarian carcinomas (Silverberg, 2000) 
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(glandular, papillary, solid), nuclear pleomorphism, and mitotic activity. Each parameter is 
given a score of 1–3 and a final grade is defined based on the summation of the scores, as 
shown in Table 1  (Silverberg, 2000).  
                
More recently, a 2-tier system, where tumors are stratified into low and high-grade, 
has been proposed by MDACC for serous carcinomas. This grading is primarily based on the 
assessment of nuclear atypia with the mitotic rate used as a secondary feature. According to 
this two-tier system, tumors with mild to moderate cytologic atypia are designated as low-
grade, whereas tumors with marked cytologic atypia as high-grade (Malpica et al, 2004). 
 
Besides the use of one of those universal grading systems there is an increasing 
tendency to employ different grading system for each histopathological subtype, as 
recommended by the Royal College of Pathologists Ovarian Cancer Datasets in the United 
Kingdom.  
 
2.3.2  Diagnosis: Symptoms and screening methods  
 
Epithelial Ovarian Cancer is called a ‘‘silent killer” due to lack of specific symptoms 
until it spreads into the pelvis and upper abdomen. In these advanced stages it manifests with 
pelvic or abdominal pain or pressure, abdominal swelling, nauseas, dyspepsia, and early 
satiety (Behtash et al, 2008). Ovarian cancer screening is preformed through pelvic 
examination, ultrasonography, computer tomography and measurements of the levels of 
CA125 serum marker, methods which are currently regarded as not specific and sensitive 
enough. 
 
Therefore, due to lack of specific symptoms and effective screening methods, 
ovarian cancer is often diagnosed at advanced stages (Heintz et al, 2006) and the estimated 
5-year survival rate of these cases is around 27% (Siegel et al, 2012). 
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2.3.3  Treatment  
 
Specific ovarian carcinoma treatment recommendations are dependent on the stage 
of the disease, however according to the consensus statement of the 4th Ovarian Cancer 
Consensus Conference of the Gynecologic Cancer InterGroup (GCIG) in 2011, the treatment 
cornerstones are the maximal cytoreductive surgery followed by platinum-taxane adjuvant 
chemotherapy (Thigpen et al, 2011).  In case of moderately and well differentiated low stage 
tumors (I and II) surgery alone may be an adequate treatment option, but should include 
hysterectomy, bilateral salpingo-oophorectomy, and omentectomy. In case of higher grade 
low stage tumors the surgery might be followed either by radiation therapy or by 
chemotherapy based on platins alone or in combination with paclitaxel. 
 
Patients with high stage tumors (III and IV) are subjected for maximal debulking 
surgery followed by a systemic standard chemotherapy based on carboplatin and paclitaxel. 
In the inoperable cases, neo-adjuvant chemotherapy is given to reduce the tumor load before 
a second attempt of surgical cytoreduction. Maximal removal of the tumor is an essential 
prognostic factor (Ramirez et al, 2011). 
 
Growing understanding of ovarian cancer landmarks in the recent years has led to 
the development of molecular-driven targeted therapies that have being more widely used in 
the combination to the standard chemotherapy. Currently the main strategies involve 
targeting angiogenesis by inhibiting VEGF pathway with bevacizumab or targeting cells with 
defective homologous recombination (e.g. BRCA1/2 mutation) with PARP inhibitors, based on 
the concept of “synthetic lethality” (Banerjee & Kaye, 2013) that assums that targeting the 
second gene from the synthetic lethal pair will selectively kill defective (tumoral) cells. 
 
2.3.4  Prognostic and predictive factors 
 
In addition to maximal cytoreduction, stage of the tumor determined according to 
FIGO system and age of initial diagnosis represent well established prognostic factors 
(Bristow et al, 2002; Heintz et al, 2003; Thigpen et al, 1993). Also growing number of 
evidence points to the association of BRCA1/2 germline mutations carriers with significantly 
better prognosis (Alsop et al, 2012; Bolton et al, 2012; Vencken et al, 2011; Yang et al, 2011). 
Specific histologic subtype and grade have been shown to have some significant relevance 
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too, however, the independent contribution of each of them after adjustment for tumor stage, 
has not been well established. 
 
In addition, several possible molecular markers have been suggested to have 
prognostic or predictive role, but few have been proven in the subsequent studies and still 
none of them is used in the clinical practice. The most recent meta-analysis evaluating few of 
them (Bcl-2, EGFR, GST, LRP, p16, p21 and TNF- α) reported lack of association with patients 
prognosis or response (Xu et al, 2013). 
 
 
2.4   RISK FACTORS 
 
The etiology of ovarian cancer is not completely revealed yet. There are many 
different factors such as genetic, but also environmental, reproductive, medical and lifestyle-
related that can modify the risk of ovarian cancer. 
2.4.1  Non-genetic risk factors  
 
Among non-genetic risk factors increasing age is far the strongest one (Cancer 
Research UK, 2013). Unlike some other cancer types, risk rates for ovarian carcinomas keep 
rising constantly until woman’s eighties. 
 
Reproductive factors 
 
Epithelial Ovarian Cancer risk is strongly modulated by reproductive and menstrual 
factors. In general all events which interrupt ovulation and decrease the total number of 
ovulatory cycles such as pregnancy, breastfeeding, and use of oral contraceptives reduce the 
risk of ovarian cancer, while those that prolong exposure to ovulation such as nulliparity and 
infertility increase that risk.  
Reproductive factors that decrease the risk of ovarian cancer include short 
menstrual history (late age of menarche and early age of menopause), early age at first birth 
as well as last pregnancy at a later age, a greater number of pregnancies and longer periods of 
breastfeeding (Siskind et al, 1997; Titus-Ernstoff et al, 2001; Whittemore et al, 1992). Oral 
contraceptives (OCs) are an established protective factor, effect of which increases with the 
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duration of OC intake (Hunn & Rodriguez, 2012; King, 2011). Whereas hormonal replacement 
therapy (HRT) increases the risk with a duration of treatment, becoming significant after 
seven years. Higher increase of risk is observed in case for oestrogen-based HRT, in contrast 
to oestrogen-progestin HRT (Pearce et al, 2009)  (Cancer Research UK, 2013).  
 
Habits and environmental factors 
 
Higher body mass index (BMI>30) (Protani et al, 2012) and height over 1.7m 
(Schouten et al, 2008) were reported to increase the risk. Other factors such as use of talk 
(Huncharek et al, 2003; Wu et al, 2009), medical radiation exposure or night-shift work have 
been reported to modify the ovarian cancer risk.   
 
2.4.2  Genetic risk factors 
 
The single greatest ovarian cancer risk factor is a family history of the disease. Having 
a single first degree relative affected with ovarian cancer increases the lifetime risk to 5% and 
to at least 7% with two or more first-degree relatives (Stratton et al, 1998).  
 
Although familial aggregation of cancer may be caused by both genetic and non-
genetic factors shared within families twin studies indicated a greater role of genetic factors 
(Lichtenstein et al, 2000).   
 
2.5   HEREDITARY EPITHELIAL OVARIAN CANCER   
2.5.1 Hereditary predisposition to ovarian cancer 
 
Hereditary nature of the ovarian carcinomas can be recognized based on the 
assessment of several features like many individuals in the affected family, earlier age of 
onset, multiple primary cancers in the same individual, bilaterallity or existence of multifocal 
cancers (Berliner & Fay, 2007). 
Hereditary carcinomas occur more often in the context of several hereditary 
autosomal dominant syndromes, among which Hereditary Breast and Ovarian Cancer 
Syndrome (HBOCS) confers the greatest risk.  Other syndromes such as Hereditary Non-
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Polyposis Colorectal Cancer (HNPCC), Peutz-Jeghers syndrome or Cowden’s disease also 
confer high risk for developing hereditary ovarian cancer, but explain only smaller 
percentage of such cases.  
 
Initially, it was believed that only around 10% of ovarian cancer cases could be 
explained by an underlying genetic syndrome, however more recent data indicate that just 2 
of them, Hereditary Breast and Ovarian Cancer Syndrome and Hereditary Nonpolyposis 
Colorectal Cancer, account for at least 20% of ovarian cases (Weissman et al, 2012b).  
 
Currently at least 25% of newly diagnosed ovarian tumors are explained by germline 
mutations in a single gene suggesting that much higher proportion of ovarian cases is 
hereditary in nature (Pal et al, 2005; Pennington & Swisher, 2012; Walsh et al, 2011). Besides 
the high-risk genes, several intermediate-risk genes have been recently identified as well as a 
number of low penetrance variants (Figure 3). Common low penetrance variants confer little 
risk individually, but when inherited in a combination may contribute to explain part of the 
familial risk.  
 
 
Figure 3. Percentage of ovarian cancer cases having familial antecedents (A) and proportion of different types 
of genetic risk explaining those cases (B) (adapted from http://www.nature.com/icogs/)  
MMR-mismatch repair; SNP-single nucleotide polymorphim; COGS-Collaborative Oncological Gene-
Environment Study; iCOGS: custom Illumina iSelect genotyping array desined by the COGS consortia 
 
 
 
2.5.2  BRCA1 and BRCA2: Hereditary Breast and Ovarian Cancer 
Syndrome (HBOCS) 
 
The strongest risk for epithelial ovarian cancer is conferred by germline mutations in 
one of two high-susceptibility genes, BRCA1 and BRCA2, which cause Hereditary Breast and 
Ovarian Cancer Syndrome (HBOCS). The HBOCS is an autosomal dominantly inherited 
disease characterized by an increased risk for breast and ovarian cancer as well as for other 
A B 
 
B 
 
A 
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neoplasms, such as prostate or pancreatic cancer. The percentage of HBOCS families 
explained by mutations in BRCA1 or two or more ovarian cancer cases can be attributed to 
germline mutations in one of these two genes (Ramus et al, 2007).  
 
The BRCA1 gene is located at 17q21 and contains 24 exons spread over 80 kb that 
encode for a 1,863 aa protein (Miki et al, 1994). The BRCA1 protein consists of four major 
protein domains: the zinc-finger RING domain located at the N-terminus, the BRCA1 serine 
domain and two BRCT domains, composed of repetitive sequences for interactions with key 
proteins involved in DNA repair or metabolism, located at the C-terminus. The BRCA2 gene, 
located at 13q12.3, contains 27 exons, 26 of which encode for a 3,418 aa protein. The BRCA2 
protein contains two functional domains known as BRC repeats essential for the DNA repair 
and interaction with RAD51. 
 
 It is estimated that in general population, approximately 0.125% to 0.20% carry a 
mutation in either of these genes (Pal et al, 2005; Walsh et al, 2011; Zhang et al, 2011). 
However, the mutations’ frequencies vary between the populations. In geographically or 
culturally isolated ethnic groups like Ashkenazi Jewish (Oddoux et al, 1996), Finnish, Islandic 
(Tulinius et al, 2002), but also in Polish (Gorski et al, 2004) and Spanish (Diez et al, 2003) 
exist population-specific mutations, called founder mutations, which have much higher 
prevalence. For instance, the prevalence of BRCA1/2 mutations in Ashkenazi Jewish ovarian 
cancer cases is 35-40%, as 2.3% of this population harbors one of three founder mutations 
(Moslehi et al, 2000; Struewing et al, 1997). 
 
The lifetime risk of developing ovarian cancer differs between the two genes and 
there have been a number of studies aiming to estimate that risk. According to two recent, 
large meta-analysis the lifetime risk for ovarian cancer was estimated to be approximately 
40% for BRCA1 and 18% for BRCA2 (Chen et al, 2006; Chen & Parmigiani, 2007), and 22% 
and 18%, respectively, in the Spanish population (Milne et al, 2008). The variation in the risk 
estimates is accounted by many factors and depends not only on the population studied, but 
also on factors like study design, patient ascertainment method, mutation type and location 
and additional genetic and environmental factors that may modify the risk. 
 
BRCA2 depends on different factors, but it has been reported that up to 50% of 
families with  
Regarding the role of BRCA1 and BRCA2 many cellular and biochemical functions of 
both genes have been discovered. Importantly they have been defined as tumor suppressors, 
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and ‘caretakers’ sensing the DNA damage and participating in the repair process. Specifically, 
both BRCA1 and BRCA2 are necessary for double-stranded DNA breaks repair by homologous 
recombination (HR). Their inactivation allows other genetic defects to accumulate leading to 
genomic instability. Loss of BRCA1 function results in defects in DNA repair, transcription, 
centrosome duplication, G2/M cell cycle checkpoint regulation, spindle formation and also in 
chromosomal instability (Brodie & Deng, 2001; Deng, 2006; Rosen et al, 2006b). Cells lacking 
BRCA2 are deficient in the repair of double-strand DNA breaks, as reflected in a 
hypersensitivity to ionizing radiation (Venkitaraman, 2001; Venkitaraman, 2002). 
 
2.5.3  Other high-risk ovarian cancer susceptibility genes 
 
In addition to BRCA1 and BRCA2 there are several other genes that confer high 
susceptibility to develop ovarian cancer in the context of other autosomal dominant tumor 
predisposition syndromes.  
The Hereditary Non-Polyposis Colorectal Cancer Syndrome (HNPCC) also known as 
Lynch syndrome explains 2-4% of ovarian carcinomas. Germline mutations in one of four 
mismatch-repair (MMR) genes (MLH1, MSH2, MSH6, and PMS2) account for approximately 
36%, 38%, 14%, and 15% of this syndrome, respectively (Palomaki et al, 2009). In addition, 
smaller proportion of affected individuals may have germline deletions in EPCAM which 
inactivate MSH2 through epigenetic silencing (Weissman et al, 2011). The cumulative risk of 
ovarian cancer associated with this syndrome is estimated to be between 4 and 11% 
(Weissman et al, 2012a; Weissman et al, 2012b), with an average age of onset of 42.7 years 
(Watson et al, 2001) and the tumors are usually moderately or well differentiated, of serous 
(32%), endometrioid (29%), mixed (24%), mucinous (19%) or clear cell (18%) histology 
(Crijnen et al, 2005).  
A small percentage of hereditary ovarian cancer cases is also explained by another 
rare (reported incidence: 1:8300 and 1:200,000 births) autosomal dominant syndrome 
known as Peutz-Jeghers syndrome (PJS) (Allen & Terdiman, 2003; Lindor et al, 2008). 
Between 50 to 90% of the patients with this disorder are explained by germline mutations in 
serine threonine kinase 11 gene (STK11) (Amos et al, 2004; Salloch et al, 2010; Volikos et al, 
2006). Individuals with PJS show an increased by 10-18 fold risk for a wide variety of 
epithelial malignancies (Giardiello et al, 2000; van Lier et al), among them, ovarian 
carcinomas. 
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2.5.4  Recently described high- to moderate- susceptibility genes  
 
In 2010 RAD51C, a gene essential in homologous recombination (HR), was found to 
present germline mutations in patients from high-risk breast and ovarian families negative 
for BRCA1 and BRCA2 mutations (BRCAX families) (Meindl et al, 2010; Vaz et al, 2010; 
Vuorela et al, 2011). A relative risk for carriers of the RAD51C muataions was estaimated to 
be 5.9, that equals to more than 9% of cumulative risk of developing ovarian cancer by the 
age 80 (Loveday et al, 2012). However, currently ongoing international study will help to 
fully clarify the frequency and risk conferred by those mutations.  
 
Identification of RAD51C mutations promped investigators to study the role of 
RAD51D, other RAD51 paralog, in cancer susceptibility (Loveday et al, 2011). Mutations were 
identified in 0.9% of BRCAX families and were more prevalent in families with more than just 
one ovarian cancer case and increased with each additional ovarian tumor. The relative risk 
of ovarian cancer for this gene is estimated to be 6.3, which confers 10% cumulative risk by 
80 years old (Loveday et al, 2011). As for RAC51C, further analysis of large series of ovarian 
cancer cases from the general population will be necessary to accurately estimate the 
frequency and penetrance of RAD51D mutations and to eventually facilitate the clinical 
implementation of these genes. 
 
Recently two rare frameshift mutations in BRIP1 
were found to be associated with markedly increased risk 
of ovarian cancer (Rafnar et al, 2011). The mutation 
identified in the Icelandic population was associated with 
8.1 times higher risk of developing ovarian cancer, while 
the one found in Spanish individuals was estimated to 
increase the risk 25 times.  
 
Recent massively parallel sequencing of 21 tumor 
suppressor genes in ovarian cancer patients identified 
deleterious germline mutations in 6 of them, which had not 
been previously associated with hereditary ovarian cancer: 
BARD1, BRIP1, CHEK2, MRE11A, NBN and RAD50 (Walsh et al, 2012). However the overall 
proportion of ovarian carcinomas explained by mutations in these genes and their 
penetrance, remain to be established and validated.  
Table 2 Genes associated with 
hereditary EOC (Pennington & Swisher, 
2012) 
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Current data, indicate existence of at least 16 genes (Table 2) (some of those still 
awaiting further evidence) that would confer high to moderate risk to ovarian cancer 
(Pennington & Swisher, 2012).   
 
2.5.5 Common low-penetrance susceptibility variants 
 
All high-susceptibility and moderate susceptibility genes described so far account for 
about 36% of familial EOC cases (Bahcall, 2013) . 
 
Several genetic models are proposed to explain residual familial inheritance; one of 
those predicts an existence of other highly penetrant, but very rare genes. 
 
      Alternatively, several more moderate risk genes could account for a remaining part of 
familial risk and multiple case families. Finally, there may be many low risk (low penetrance) 
genes that individually would confer small relative risks, but whose combined inheritance 
would contribute to risk increments.  
 
Results from the Collaborative Oncological Gene-Enviroment Study (COGS) using a 
large-scale genome-wide association meta-analysis have confirmed previously reported 
ovarian cancer risk variants and described new ones. In total 12 ovarian cancer susceptibility 
loci located at 2q31, 3q25, 8q21, 8q24, 9p22.2, 10p12, 17p12, 17q12, 17q21 and 19p13 and 
5p15 (two variants in this locus) were identified (Bojesen et al, 2013; Bolton et al, 2010; 
Goode et al, 2010; Permuth-Wey et al, 2013; Pharoah et al, 2013; Song et al, 2009; White et al, 
2010). Very recently, two additional variants at the NF-Kb pathway genes: IL1A and TNFSF10 
have also been reported (Charbonneau et al, 2014). However, altogether these alleles explain 
only 4% of excess familial aggregation (Figure 3B) and their effects on risk are modest, 
varying from 0.63 and 1.48 (Pharoah et al, 2013). On the basis of what is known about the 
architecture of genetic susceptibility for other cancers, it is probable that many more 
common susceptibility alleles exist, accounting for the most of 60% of unexplained 
inheritance (McClellan & King, 2010; Pharoah et al, 2013).  
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2.5.6 Clinical features of hereditary EOC 
 
Hereditary ovarian tumors are usually diagnosed in younger patients, especially those 
in BRCA1 mutation carriers (52-55 yrs) and only slightly earlier in BRCA2 carriers (59-60yrs) 
than in general population (60-62yrs), which is consistent with different penetrance rate of 
those genes (Alsop et al, 2012; Bolton et al, 2012; Walsh et al, 2011; Yang et al, 2011). 
 
 Despite the fact that most of the BRCA1/2 carriers are diagnosed at advanced stages 
(Pennington & Swisher, 2012; Walsh et al, 2012) and their tumors seem to show more 
aggressive characteristics, they have been reported to be associated with favorable survival 
outcomes, some studies referring it only to BRCA2-mutation carriers (Bolton et al, 2012; 
Hyman et al, 2011; TCGA, 2011; Yang et al, 2011). This more favorable outcome for BRCA 
mutation carriers is likely to be associated with increased sensitivity of BRCA-deficient cells, 
that have impaired homologous recombination repair (HR), to cytotoxic drugs such as 
platinum-based agents (Alsop et al, 2012; Bolton et al, 2012; Vencken et al, 2011; Yang et al, 
2011). Greater survival advantage observed specifically in BRCA2-carriers has been 
associated with different role of both BRCA genes in DNA double strand repair, with BRCA2 
being more directly involved in the homologous recombination itself (Hyman et al, 2011; 
Yang et al, 2011). 
 
2.5.7  Immunohistopathological features of hereditary EOC 
 
Ovarian carcinomas associated with BRCA1/2 mutations present a distinct 
histopathological phenotype, with the majority being high-grade serous of solid type (Bolton 
et al, 2012; Boyd et al, 2000; Evans et al, 2008; Lakhani et al, 2004; Mavaddat et al, 2012). 
Besides serous histology BRCA1/2 mutation carriers are also represented (to lower extent) 
by other high grade subtypes, including endometrioid, clear cell and undifferentiated 
carcinomas. In contrast mucinous and borderline neoplasms account only for about 2% of 
those cases (Evans et al, 2008).  BRCA1-associated high grade serous carcinomas would also 
show specific cell morphology, presenting solid, pseudoendometroid and transitional cellular 
type, higher mitotic index and greater number of tumor infiltrating lymphocytes (Soslow et 
al, 2012).  
 
Immunohistochemical characteristic of familial ovarian tumors is poorly established 
due to few existing studies, usually small sample series and lack of conclusive results. 
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However, p53 overexpression is the most consistently reported feature of BRCA1/BRCA2 
mutation cases (Lakhani et al, 2004; Munoz-Repeto et al, 2013). In addition a study that 
included 40 immunohistochemical markers found an association of BRCA1-related ovarian 
carcinomas with higher expression of progesterone receptor and nuclear EGFR, the later 
being more frequently overexpressed also in BRCAX (65%) tumors (in contrast to BRCA2-
related carcinomas (19%) (Munoz-Repeto et al, 2013). 
 
2.5.8  Gene expression pattern of hereditary EOC 
 
So far there have been few studies aiming to characterize gene expression profiles in 
hereditary ovarian carcinomas. One such study described a gene expression signature that 
would discriminate between BRCA1- and BRCA2-mutant tumors allowing classification of 
sporadic cancers as either BRCA1- or BRCA2-like (Jazaeri et al, 2002). However, a recent 
study did not replicate these findings, reporting BRCA1-mutated tumors as the outlier group 
in gene expression, with BRCA2 and wild-type tumors being more closely related (George et 
al, 2013b). Other study found similar gene expression profiles in BRCA1 mutated and BRCA1 
wild-type tumors (just two genes being defined as differentially expressed) and also in the 
group with epigenetically silenced BRCA1 (no genes identified as differentially expressed) 
(Pradhan et al, 2010).  
 
2.6   DNA COPY NUMBER CHANGES IN EOC 
2.6.1  Genomic instability in cancer 
 
Somatic chromosomal copy number alterations and rearrangements are a cardinal 
feature inherent to almost all solid tumors and lead to altered expression and function of 
genes residing within the affected region of the genome (Albertson et al, 2003; Mitelman, 
2000). Such structural changes are consequences of underlying genomic instability leading to 
chromosomal missegregation and repetitive cycles of DNA strand breaks and rejoining. Since 
such alterations commonly harbor either oncogenes or tumor suppressor genes depending 
on whether they are present in increased or decreased copy number, respectively, their 
proper identification is crucial. Defining DNA copy number altered regions and especially the 
genes involved, offers a basis for better understanding of a cancer development and more 
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importantly, provides improved tools for clinical cancer management, such as new 
diagnostics and therapeutic targets. 
 
2.6.2  DNA copy number variation detection methods 
 
Historically, cytogenetic analysis of Giemsa-stained metaphase chromosomes was 
applied to ascertain chromosomal abnormalities. This technique was used to identify 
balanced and unbalanced structural and numerical chromosomal changes, however  it was 
not sensitive enough to detect subtle rearrangements (less than 4 Mb). Further 
implementation of fluorescent in situ hybridization (FISH) improved the diagnostic resolution 
and, until recently, had been considered the method of choice for detecting chromosomal 
imbalances and rearrangements. However, this technique is  
time-consuming and targeted,  meaning that requires prior knowledge of the chromosomal 
region(s) of interest and therefore interrogates one or more candidate chromosomal loci at a 
time.  
Only the development of comparative genomic hybridization (CGH) in 1992 
(Kallioniemi et al, 1992), which was initially invented as a molecular tool in cytogenetics, 
opened the possibility for genome-wide copy number screening. CGH effectively reveals any 
DNA copy number changes (i.e., gains, amplifications, or losses) that are present in at least 
30–50% of the specimen cells (Kallioniemi et al, 1994). However, it does not detect balanced 
translocations, inversions, and other aberrations that do not change copy number. The  
theoretical detection limit of CGH has been estimated to be about 2 Mb (Piper et al, 1995).  
 
Substitution of the metaphase chromosomes with array-based CGH (aCGH) 
established by Solinas-Toldo et al (Solinas-Toldo et al, 1997)  and further refined by Pinkel et 
al (Pinkel et al, 1998) has simplified the analysis procedure and solved many technical issues 
connected with cytogenetic chromosome preparations. However, the main advantage of this 
new aCGH technique was the ability to perform copy number analyses with much higher 
resolution, than was ever possible using chromosomal CGH (Davies et al, 2005; Lockwood et 
al, 2006; Pinkel & Albertson, 2005).    
 
  In aCGH, equal amounts of labeled genomic DNA from a test and a reference sample 
are co-hybridized to an array containing the DNA targets. Those interrogating probes 
(targets) used for the microarrays’ construction are pieces of human genomic DNA, initially in 
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the form of yeast artificial chromosome (YAC; 0.2–2 Mb in size),  bacterial artificial 
chromosomes (BACs) or P1 (PAC) clones (size of 75–200 kb), smaller insert clones such as 
cosmids (size of 30–40 kb) and fosmids (size of 40–50 kb), or more recently oligonucleotides 
(25–85 mers) that are automatically spotted and immobilized onto glass slides using split 
metal pins or glass capillaries. 
In aCGH, either a pool male/female DNA, or, more reliable, matched normal DNA from 
the same person are used as a reference. Genomic DNA from the patient and reference are 
labeled with fluorescent dyes and hybridized onto the sildes containing the arrayed probes 
from the genome. Slides are scanned and the spots’ intensities are measured and quantified 
using feature extraction software. The resulting ratio of the fluorescence intensities is 
proportional to the ratio of the copy numbers of DNA sequences in the test and reference 
genomes. If the intensities of the dyes are equal the region is interpreted as having equal 
quantity of DNA in the test and reference samples; if the ratio is altered indicates either a loss 
or a gain of the patient DNA at that specific genomic region.  
In addition to aCGH, high-density SNP arrays, principally developed to detect single 
nucleotide variation, have become more popular for copy number profiling. The advantage of 
SNP arrays is, that in contrast to standard aCGH they are able to detect loss of heterozygosity 
events (LOH) and copy number-neutral LOH in form of acquired uniparental disomy (UPD). 
These type of regions are particularly interesting in cancer research, because of their 
probability of containing either a mutated tumor suppressor gene (TSG) or oncogene with 
loss of their normal allele (Nowak et al, 2009). However, they have also some limitations, 
because SNPs in these arrays are not uniformly distributed across the genome and are sparse 
in regions with segmental duplications or complex aberrations (Carter, 2007). To overcome 
these limitations, the new generations of SNP genotyping arrays have now incorporated 
additional nonpolymorphic (NP) markers to provide more comprehensive coverage of the 
human genome.  
 
Recently emerging next-generation sequencing technologies provide increasingly 
high-resolution analyses of copy-number alterations in cancer genomes. They enable to 
achieve extremely high resolution, more than 3 times higher than the current generation 
microarrays. Therefore they overpower traditional microarrays in the precision of mapping 
chromosomal breakpoints and detection of extremely small intragenic events. In addition, 
they are also able to detect structural rearrangements and minimize the effect of the 
contamination of the tumor sample with normal cells by performing deeper sequencing 
(Campbell et al, 2008; Chiang et al, 2009). However the cost and to some extent the analysis 
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and interpretation of the obtained data is still a bottle neck for their wide implementation in 
the copy number analysis (Chiang et al, 2009; Shendure, 2008). 
2.6.3 DNA copy number changes in familial and sporadic EOC 
 
As for other tumor types DNA copy number profiling has been widely applied in 
ovarian cancer research in order to define the genomic aberrations in the tumors, search for 
genes involved in the carcinogenesis of particular cancer subtypes, get more insight in 
diagnostic classification and assessment of tumor progression or patients’ prognosis.  
 
Since late 1960s, when the first karyotypes of ovarian cancer were published 
(Yamada et al, 1966) it was clear that epithelial ovarian cancer is characterized by highly 
aneuploid cells with high heterogeneity both within and between individual cases. 
Improvements in cytogenetic techniques lead to the publication of more than 150 ovarian 
cancer karyotypes by 1990 (Mitelman, 2008) but only the development of the comparative 
genomic hybridization (CGH) in 1992  (Kallioniemi et al, 1992) enabled identification of the 
most common DNA copy number changes.  By 2000, the most frequent gains such as: 8q, 3q, 
1q and 20q and losses at 4q, 5q, 8p, 22q, 18q and 17p had been well annotated, however 
identification of specific target genes remained problematic due to high cytogenetic 
complexity and heterogeneity of ovarian cancer (Gorringe & Campbell, 2009). Currently 
HGSOCs, as the most common and aggressive subtype, are getting a lot of researchers’ 
attention. The most recent and comprehensive study of HGSOC carried out by The Cancer 
Genome Atlas (TCGA) revealed that these tumors are characterized by surprisingly high level 
of genomic instability with complex chromosomal alterations, which is in contrast to many 
other solid tumors (Bowtell, 2010; TCGA, 2011). That study identified 8 recurrent gains and 
22 losses, all of which had been previously reported. Five of the gains and 18 of the losses 
occurred in more than 50% of the tumors. 
 
Although sporadic EOC tumors have been quite extensively studied, much less is 
known about DNA copy number changes in hereditary ovarian tumors. 
 
The few existing studies have rendered contradictory results, either reporting no 
significant differences in the number of genetic alterations between hereditary and sporadic 
cases (Ramus et al, 2003; TCGA, 2011; Zweemer et al, 2001), or on the contrary observing 
higher genomic instability in hereditary cases (Israeli et al, 2003; Patael-Karasik et al, 2000). 
Also divergent data have been produced regarding global degree of genomic instability or 
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type of dominating alterations, indicating higher contribution of gains (Israeli et al, 2003) or 
losses (Leunen et al, 2009) in the overall genomic instability of hereditary cases. Such 
contradictory results, might be due to the limited number of tumors included (Israeli et al, 
2003; Leunen et al, 2009; Patael-Karasik et al, 2000), the use of low resolution techniques 
(Patael-Karasik et al, 2000; Ramus et al, 2003; Zweemer et al, 2001) or application of 
different algorithms (Leunen et al, 2009; TCGA, 2011) (Table 3). 
 
 
 
BRCA impared: tumors with BRCA1/2 germline or somatic mutations or BRCA1 methylation; all other 
BRCA1/2 in Table refer to tumors from germline mutation; HGSOC-High Grade Serous Ovarian Carcinomas; 
HNPCC- Hereditary Non-Polyposis Colorectal Cancer 
 
2.6.4  DNA copy number changes as clininaly relevant markers  
in EOC 
 
Few of the studies focused on describing DNA copy number changes in sporadic or 
familial epithelial ovarian aimed to define specific aberrations that may have clinical 
relevance in predicting outcome in ovarian cancer (Baumbusch et al, 2013; Bruchim et al, 
Table 3. Summary of a few existing CGH studies on familial EOC  
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2009; Engler et al, 2012; Hu et al, 2003; Nanjundan et al, 2007; Suzuki et al, 2000; Wang et al, 
2012b; Yamamoto et al, 2009).  
 
Some markers that may be applied in predicting tumor progression and recurrence 
have been described (Bruchim et al, 2009; Hu et al, 2003; Wang et al, 2012a). For example 
higher risk of recurrence has been proposed to be associated with 5p gain, while 1p gain and 
5q loss with its decrease (Bruchim et al, 2009). Also, amplification at 5q31–q35 has been 
linked to poor prognosis, while 4p16 loss to better outcome (Birrer et al, 2007).  
Nevertheless, most studies that focused on assessment of specific alterations were limited by 
an absence of independent copy number validation datasets (Bruchim et al, 2009; Hu et al, 
2003; Nanjundan et al, 2007; Yamamoto et al, 2009). Other studies including independent 
validation series were mainly focused on description of general features (ie. genomic 
instability or LOH profiles) more difficult to implement in the clinic than distinct individual 
changes (Baumbusch et al, 2013; Wang et al, 2012a).   
 
In order to define novel prognostic and predictive markers in EOC some limitations 
have to be addressed.  Among them, the use of large discovery series and high-resolution 
platforms; availability of clinical data that allow to adjust the results for already established 
prognostic factors and, very important, robust validation.  
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It has been reported that hereditary and sporadic EOC present distinct 
oncogenic pathways. However, little is still known about their resemblance or 
divergence at the genomic level. Given the recently confirmed relevance of DNA copy 
number changes as drivers of ovarian oncogenesis and the growing clinical 
implications of the BRCA1/2 mutation status, we proposed the following objectives:  
 
1. To characterize the genomic alteration profiles of familial (BRCA1, BRCA2 
and BRCAX) and sporadic EOC at high resolution level in order to:  
 
› Describe the general rate and pattern of genomic instability in 
the different tumor groups   
 
› Define altered regions, genes and pathways common to all 
tumor groups and specific to each of them 
 
2. To find associations between DNA copy number-based groups of EOC and 
immuno-histopathological and clinical features  
 
3. To define DNA copy number changes with prognostic and/or predictive  
value 
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Se ha descrito que los CEO hereditarios y esporádicos presentan diferentes 
vías oncogénicas. Sin embargo todavía se conoce poco acerca de sus similitudes o 
diferencias a nivel genómico. Recientemente se ha confirmado el importante papel 
que tendrían las alteraciones en el número de copias de ADN en la oncogénesis de los 
tumores de ovario. Teniendo esto en cuenta y también la creciente implicación clínica 
de las mutaciones en los genes BRCA1 y BRCA2, hemos propuesto los siguientes 
objetivos:  
 
1. Caracterizar los perfiles de alteración genómica de los CEO familiares 
(BRCA1, BRCA2 y BRCAX) y esporádicos con herramientas de alta 
resolución para:  
 
› Describir los niveles y patrones generales de inestabilidad 
genómica en los distintos grupos de tumores 
 
› Definir alteraciones en regiones, genes y rutas celulares comunes 
entre los distintos grupos de tumores y específicos de cada uno de 
ellos 
 
2. Determinar si grupos de CEO definidos de acuerdo con su patrón de 
alteraciones genómicas presentan asociación con características 
immunohistopatológicas y clínicas  
 
3. Definir alteraciones en el número de copias de ADN con valor pronóstico 
y/o predictivo  
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1 PATIENTS AND TUMORS 
 
1.1  DISCOVERY SERIES 
 
Discovery series consisted of 75 formalin-fixed paraffin-embedded (FFPE) 
epithelial ovarian tumors. Fifty-seven corresponded to patients from high-risk breast 
and ovarian cancer families (21 with mutation in BRCA1, 6 with mutation in BRCA2 
and 30 without either mutations) and 18 to sporadic cases.  
Families selected for this study fulfilled one of the following criteria:  (a) at least 
two cases of ovarian cancer in the same family line; (b) at least one case of ovarian 
cancer and at least one case of breast cancer in the same family line; (c) at least one 
woman with both breast and ovarian cancer; (d) at least one woman with bilateral 
ovarian cancer. All families were ascertained at the Spanish National Cancer Research 
Center (CNIO) familial cancer consultancy and at different Spanish hospitals: Hospital 
Fundación Alcorcón, Hospital Doce de Octubre, Fundación Jiménez Díaz and Hospital 
Ramón y Cajal (Madrid); Hospital Sant Pau (Barcelona); Hospital Donostia (San 
Sebastian); Hospital General de Albacete (Albacete). Index cases were analyzed for 
germline mutations throughout the coding regions and splice site boundaries of the 
BRCA1 and BRCA2 genes by a combination of different methods including denaturing 
high performance liquid chromatography (DHPLC) and direct sequencing (Beristain 
et al, 2007; de la Hoya et al, 2001; Diez et al, 2003; Llort et al, 2002; Milne et al, 2008; 
Osorio et al, 2000). Individuals with no mutations in BRCA1 or BRCA2 genes were 
designated as BRCAX cases. Ovarian tumors from index cases, confirmed carriers or 
non-tested obligate carriers were collected from BRCA1 and BRCA2 positive families. 
Tumors from index cases and first-degree relatives of index cases were collected from 
BRCA1/2 negative families (BRCAX families).  
Sporadic cases (with no reported first or second degree relative with breast or 
ovarian cancer) were obtained from one single institution (Hospital Virgen del Rocio, 
Sevilla) and were selected to match the histopathological distribution of the familial 
series.  
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The study was approved by The Ethical Committees of the participating 
centers and written informed consent was given by each individual involved in the 
study. 
 
1.1.1 Histopathological classification of tumors 
 
All tumors were blindly reviewed by two pathologists (Ivan Muñoz-Repeto and 
Jose Palacios) and classified histopathologically. Immunohistochemical expression of 
markers such as Wilms Tumor protein (WT1), tumor protein p53 (TP53), estrogen 
receptor (ER), progesterone receptor (PR) and cyclin-dependent kinase inhibitor 2A 
(p16) (CDKN2A) was performed in order to assist in the differential diagnosis 
(Kalloger et al, 2011; Kobel et al, 2009). The antibodies, dilutions, suppliers, 
visualization systems, immunostainers and scoring of the staining are shown in 
Supplementary Table 1. Grading of serous tumors was performed according to two-
tier M. D. Anderson Cancer Center (MDACC) system (Gilks et al, 2008; Malpica et al, 
2004) while the rest of the histological types were graded according to World Health 
Organization criteria (Organization, 2004; Silverberg, 2000).  
A subgroup of tumors within the type II carcinomas was defined in order to 
allow for comparisons between more homogenous groups of high-grade neoplasms.  
This subgroup consisted of high-grade serous tumors of solid growth pattern and 
undifferentiated carcinomas (hereafter referred as to “subgroup of type II tumors”). 
Detailed information is shown in Table 4.  
 
1.1.2 Patients´ clinical data 
 
Comprehensive clinical data (e.g. FIGO stage, response to the therapy and 
survival data) was retrieved with an approved clinical form from all the patients and 
summarized in Table 4.  
Included patients were diagnosed and underwent surgical intervention between 
1990 and 2008. Surgical resections were classified as optimal (less than or equal 
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1cm) or suboptimal (greater than 1cm diameter of residual tumor). Progression Free 
Survival (PFS) was calculated from the date of primary surgery to the date of disease 
progression as specified by a rise in CA125 or radiological or surgical evidence of 
relapse. The length of Overall Survival (OS) was defined from the date of primary 
laparotomy to the date of patient death. For both analyses, time was censored at the 
date of the last follow-up. 
Overall Survival (OS) data was available for 76% (n=52) of the patients, while 
Progression Free Survival (PFS) for 57% (n=39) of the patients. Median follow up 
time for was 67 months (95% CI: 59-75): 72 months (95% CI: 62-82) for familial and 
36 months (95% CI: 12-60) for sporadic cases. Platinum sensitivity was defined as 
progression free survival of more than 6 months after the last dose of platinum-based 
adjuvant therapy and was observed in 26 out of 31 patients (83%) for whom 
sufficient clinical information was available. Response to chemotherapy was 
evaluated retrospectively according to the World Health Organization evaluation 
criteria (Miller et al, 1981). This evaluation was based on data from medical records 
describing patients´ clinical condition and CA125 levels at 3–4 week intervals. 
Complete remission (CR) was defined as disappearance of all clinical and biochemical 
symptoms of ovarian cancer evaluated after completion of first-line chemotherapy 
and confirmed at 4 weeks. 
 
1.2 INDEPENDENT VALIDATION SERIES 
 
Two independent series were used to validate the associations of 6q24-26 
deletion with patient´s outcome.  
 
The first series was composed of 103 EOCs randomly distributed on 4 tissue 
microarrays (TMAs). It contained 77 sporadic and 26 familial tumors (7 BRCA1, 9 
BRCA2, 10 BRCAX) with available clinical data. Forty-nine per cent of tumors in this 
series were classified as serous (35% HGSOCs and 14% LGSOCs), 24% as clear cell 
carcinomas, 14% as endometrioid and 13% as others (including 1% with missing 
information).  More than half of them (59%) were of high FIGO stage (III and IV). 
Patients were diagnosed and underwent surgical intervention between 1991 and 
Materials and Methods  
Page | 72  
 
2010. Definition and evaluation of clinical data variables was conducted as specified 
for the discovery series.   
 
The second series consisted of 411 high grade ovarian serous ovarian 
carcinomas (HGSOC) from The Cancer Genome Atlas (TCGA) with publically available 
DNA copy number and clinical data (TCGA, 2011). This series included mainly 
sporadic (91%), high grade (87%), and high (III and IV) FIGO stage (95%) serous 
adenocarcinomas. 
 
In addition, 1436 EOCs with gene expression and clinical data available from 
the online survival analysis tool - Kaplan Meier plotter (Gyorffy et al, 2012) were used 
for validation at the gene expression level. This large dataset of EOCs is a unification 
of 10 different gene expression studies using Affymetrix platform. Available tumors 
were mainly serous (74%), high FIGO (72%), and high grade (61%) EOCs. 
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2 METHODS 
 
2.1 TISSUE MICROARRAYS (TMAs) CONSTRUCTION 
 
Ovarian tumors from the discovery and the first validation series were placed 
on 4 TMAs that were constructed as previously described (Munoz-Repeto et al, 2013; 
Palacios et al, 2003). Briefly, representative areas of the tumors selected based on 
hematoxylin and eosin-staining (HE) were marked on individual paraffin blocks. Then 
two tissue cores (1-mm diameter) for each specimen were obtained from the selected 
area as shown in the Figure 4. These tissue cores were arrayed in a predetermined 
order into a receptor paraffin block using a tissue microarray workstation (Beecher 
Instruments, Silver Spring, MD), in the Immunohistochemistry Unit at the CNIO. In 
addition, at least 2 non-neoplastic control tissues (amygdala and/or ovarian) were 
included in each TMA.  
 
  
 
 
 
 
 
 
 
Figure 4. Construction of tissue microarrays: (A) Cylindric tissue cores are removed from a 
conventional ('donor') paraffin block using a tissue microarrayer; these are released into premade 
holes of an empty ('recipient') paraffin block. Regular microtomes can be used to cut tissue microarray 
sections. (B)  Overview of a haematoxylin-eosin (H&E) stained TMA section. Each tissue spot measures 
0.6 mm in diameter. (C–E) Examples of magnifications of sectors from tissue spots from different 
experiments. (C) H&E staining (D) Immunohistochemistry (E) FISH analysis (adapted from (Sauter et 
al, 2003) 
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2.2  IMMUNOHISTOCHEMICAL ANALYSIS  
 
2.2.1 Immunohistopathological characterization of the tumors 
 
The immunohistochemical staining was performed on the 4 previously built 
TMAs using 30 IHC markers and the EnVision method with a heat-induced antigen 
retrieval step at the Immunohistochemistry Unit at CNIO. The expression of the 30 
markers was assessed independently by two pathologists Ivan Muñoz-Repeto and 
Jose Palacios. Evaluated proteins were involved in a variety of different cellular 
processes such as hormone signaling (ER, PR and AR), proliferation (topoisomerase 
IIα, Ki-67), cell cycle (CCND1, CCNE1, CDKN2A, p21, p27, p53, RB1, β-tubulin III ), 
apoptosis (BCL-XL, survivin), cell adhesion (E-cadherin), tumor progression (KLK7, 
MMP7, PIK3CA), angiogenesis (CD105, VEGF), signaling (C-KIT, EGFR, β-catenin) or 
DNA repair (ERCC1, XPG, XPF, RAD50, RAD51 and CHEK2). The antibodies, dilutions, 
suppliers, visualization systems, immunostainers and scoring used are shown in 
Supplementary Table 1. Between 100 and 150 cells per core were scored to determine 
the percentage of positive nuclei, cytoplasm, or membranes, depending on the 
marker. Nuclear staining was evaluated for ER, PR, AR, p53, Ki-67, CCND1 and CCNE1, 
p27, p21, RB1 topoisomerase IIα, survivin, RAD50, RAD51, XPF, XPG, CHEK2, ERCC1, 
EGFR, MMP7, KLK7, PIK3CA, E-cadherin and β-catenin. Cytoplasmic staining was 
assessed for CDKN2A, BCL-XL, survivin, VEGF, C-Kit, EGFR, E-cadherin and β-catenin. 
Membrane staining was evaluated for EGFR, E-cadherin and β-catenin. The 
thresholds to determine over-expression of each marker were established based on 
literature (Supplementary Table 1) as described elsewhere  (Bali et al, 2004; Brun et 
al, 2008; Duncan et al, 2008; Honrado et al, 2005; Lin et al, 2001; Ni et al, 2004; 
Raspollini et al, 2004; Rosen et al, 2006a; Schindlbeck et al, 2007; Schmandt et al, 
2003; Steffensen et al, 2009; Tangjitgamol et al, 2009; Xia et al, 2009). The percentage 
of stained nuclei, independent of the intensity, was scored for ER, PR, AR, Ki-67, p53, 
CCND1, CCNE1, p27, p21, RAD51, XPF, XPG, CHEK2, ERCC1, EGFR, MMP7 and KLK7. 
For EGFR, E-cadherin and β-catenin expression, the percentage of cells with 
membrane staining and staining intensity was determined.  
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2.2.2 Immunohistochemical validation of aCGH results   
 
Three of the evaluated antibodies targeting genes altered by high-amplitude 
events (homozygously deleted CDKN2A and RB1 and amplified CCNE1) were used to 
validate the aCGH hybridizations and analytical approaches. Expression levels in the 
amplified and deleted samples were compared to the mean expression levels in 
tumors with normal DNA copy number status at the corresponding locus (according 
to the aCGH profiles).  
 
2.3 aCGH: HYBRIDIZATIONS AND DATA PRE-PROCESSING  
 
2.3.1 DNA isolation and labeling 
 
Total genomic DNA was extracted from three 10-μm-thick FFPE tissue sections 
per tumor. After deparaffination and rehydration, sections were hematoxylin and 
eosin (HE) stained and tumor areas were delimited by a pathologist and 
macrodissected with a surgical blade to ensure at least 80% tumor content. Tumor 
and conserved normal tissue (when available) were separately dissected and placed 
in independent tubes. DNA extraction was carried out according to standard 
protocols including overnight proteinase K digestion and a column-based 
commercially available kit following the manufacturer´s instructions (QIAamp DNA 
mini kit; Qiagen, Westburg, Leusden, The Netherlands). DNA quantity and quality was 
assessed using the NanoDrop ND-1000 UV-VIS Spectrophotometer version 3.2.1. 
(Nanodrop Technologies, Wilmington, DE, USA).   
Labeling of test and reference DNA was performed with the Enzo Agilent aCGH 
labeling kit according to the manufacturer´s instructions (Enzo Life Sciences, 
Farmingdale, NY, USA). Briefly, 500 ng genomic DNA was combined with a mixture of 
random primers and reaction buffer to a final volume of 39μl. The DNA was 
denatured at 990C for 10 min, and placed on ice. While on ice, 10μl cyanine 3-dUTP 
and cyanine 5-dUTP nucleotide mixture was added to the test and reference DNA, 
respectively. At the end 1μl of Klenow DNA polymerase was added to each sample. 
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After 4 hr incubation at 370C, 5μl stop buffer was added to stop the reaction. Labelled 
DNA was purified using the QIAquick PCR Purification Kit (Qiagen, Westburg, 
Leusden, NL). DNA yield and specific dye incorporation was measured with 
NanoDrop.  
DNAgenomicLperg
dyeLperpmol
tivitySpecificAc
 
Only samples with specific activity >15 were used for hybridizations. 
 In 45 out of 75 hybridizations (60%) patient-matched normal DNA was used 
as a reference (in 26 from conserved normal tissue within the paraffin blocks and in 
19 from the patient´s peripheral blood). In the remaining 30 hybridizations (40%) a 
pool of normal DNA from 20 healthy females was used as a reference 
(http://www.kreatech.com/products/megapool-reference-dna.html).   
 
2.3.2 Hybridizations 
 
Hybridizations and preprocessing of the data were carried out in Department 
of Pathology (Microarray Core Facility) and Department of Epidemiology and 
Biostatistics at the VU University Medical Center Univeristy. The slides used for 
hybridizations contained four arrays, each with 180,880 in situ synthesized 60-mer 
oligonucleotides (4x 180K, Agilent Technologies, Palo Alto, CA) representing 169,793 
unique chromosomal locations evenly distributed across the genome (space ~ 17kb), 
and 4,548 additional unique oligonucleotides, located at 238 of the Cancer Census 
genes (http://www.sanger.ac.uk/genetics/CGP/Census/). Cy5-Labeled tumor DNA 
was combined with an equivalent amount of Cy3-labeled reference DNA in a total 
volume of 39 μl and mixed with 11μl of 10x blocking agent (Agilent Technologies) 
and 55μl of 2x hybridization buffer (Agilent Technologies).  In addition 6.5 μg of 
human Cot-1 DNA (Invitrogen, Breda,NL) was used to block repetitive sequences. The 
hybridization mixture was heated at 950C for 3 min and immediately incubated at 
370C for 30 min. After centrifugation for 60 sec at 14,000rpm, the hybridization 
mixture was applied to the slide and placed in an assembly chamber for 24 hr at 650C 
and 20 rpm (Agilent Technologies). Next, slides were washed in the following steps: 1 
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min in the wash buffer 1 at room temperature (RT), 5 min with wash buffer 1 at RT 
with rotation speed (~750 rpm), 1 min with wash buffer 2 at 370C with rotation 
speed (~750 rpm), and finally 1 min in acetonitrile at RT. 
 
2.3.3 Scanning and image acquisition  
 
Hybridized slides were scanned with Agilent Array scanner MAF0013 
(Agilent Technologies), with the laser set to 635nm, Power at 80 and a scan 
resolution of 3μm. To avoid ozone bleaching, microarrays were scanned in an ozone-
free environment (less than 2 ppb ozone). Agilent Feature Extraction software 
(version 9.5.3) (Agilent Technologies) was used for quantification of the fluorescence 
intensities of scanned images. Local background was subtracted from the median 
intensities of both Cy3 and Cy5 channels. The tumor to normal ratio was calculated 
for each probe, then log2 transformed (log2 ratio) and normalized against the median 
of the ratios of all autosomes. Reproducibility and reliability of each single microarray 
was assessed using Quality Control metrics, which included computation of the 
average green and red signal intensity at all the probes and using non-hybridizing 
control probes and quantification of background signal (noise) and signal-to-noise 
ratio. Average signal intensity >150 with signal-to-noise ratio >20 were regarded as 
satisfactory. Schematic representation of the aCGH method is shown in Figure 5. 
The oligonucleotides were mapped according to the human genome build 
NCBI36/hg18 assembly (March 2006).  
 
2.3.4 Deposition of the aCGH raw data in a public database 
 
The aCGH raw data generated in this study have been deposited at NCBI's 
Gene Expression Omnibus (Edgar et al, 2002) and  are accessible through GEO 
accession number GSE41253 (http://www.ncbi.nlm.nih.gov/geo/query/ 
acc.cgi?acc=GSE41253).  
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Figure 5. Scheme of two-color aCGH  Step 1-3 Normal (control) and tumor DNA are labeled and applied to 
the slides containing the arrayed probes from the genome Step 4 Tumor and control DNA compete with each 
other to hybridize to the oligonucleotides on the array; Step 5-6 Scanner measures the spots’ intensities and 
quantify them using feature extraction software  
 
 
2.3.5  Data normalization, segmentation and calling 
 
Data were processed in the R programming environment v.2.13 
(http://www.r-project.org). The log2 tumor-to-normal ratio was calculated for each 
spot and normalized to the median values of autosomes. Sex chromosomes were 
excluded from the analysis. 
Possible wave bias was removed with the Wave Smoothing method (van de 
Wiel et al, 2009). Segmentation and calling was done with DNAcopy algorithm 
implemented in CGHcall v.2.5 with cellularity set to 0.7 and median normalization. 
Segments with a probability score higher than 0.5 were considered amplified, gained 
or lost and corresponding ordinal values were assigned (2,1,-1, respectively and 0 in 
no copy number change).  
 
Tumor 
DNA 
 
Normal 
(control
) DNA 
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Visualization and further analysis of data was performed in Nexus Copy 
Number v5.1 (BioDiscovery, Inc; El Segundo, CA). For defining the exact location of 
amplifications, gains and losses called data was used. For determination of  
homozygous deletions raw log2 data were applied to Nexus Copy Number v5.1 and 
Rank Segmentation algortim was used with the following settings:  a significance 
threshold: 1.0E-5 , maximum contiguous probe spacing of: 1,000 kb and minimum 
number of probes per segment: 3, was used. 
Although the use of patient-matched normal and tumor samples in most 
hybridizations allowed elimination of germline polymorphic copy number variants 
(CNV), genomic regions covered entirely by CNVs previously described  in the human 
genome (from The Center for Applied Genomics’ Database of Genomic Variants, 
http://projects.tcag.ca/variation/tableview.asp?table=DGV_Content_Summary.txt) 
were removed from the analysis. Cancer Census genes located at the defined regions 
were obtained from http://www.sanger.ac.uk/genetics/CGP/Census/.  
 
 
2.4 aCGH:  DOWNSTREAM DATA ANALYSIS 
 
2.4.1 Overall genomic instability rate: number and length of 
alterations  
 
To determine the degree of genomic instability in each subgroup of tumors 
(BRCA1/2/X and sporadic), total number of alterations and number of alterations of a 
particular type (homozygous deletions/losses/gains/amplifications) per sample 
were calculated. Also, total size of altered genome and size accounted by gains and 
losses were calculated by adding up the lengths of individual segments. Next, average 
number of changes and average size of altered genome were calculated for sporadic 
tumors and for each group of familial tumors. Also, in order to determine the relative 
contribution of each type of change (losses or gains) we computed the ratio of the 
average number of losses to the average number of gains within each tumor subtype. 
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Similarly, we calculated the ratio of the average lost genome length to the average 
gained genome length.  
 
2.4.2 Common and potentially specific altered regions  
 
In order to visualize the general pattern of chromosomal changes, frequency 
plots were generated and a list of recurrent Minimal Common Regions (MCRs) of 
alterations for each tumor subtype (BRCA1/2/X and sporadic) were defined using 
Nexus software with  “Aggregate cut off” (minimum frequency) of 25% and the 
“Peaks Only” option to refine the size of the altered region. High-amplitude DNA copy 
number changes (amplifications and homozygous deletions) were considered 
recurrent when present in at least two cases from the group. MCRs for each group has 
been defined with minimum frequency of 25% for gains and 35% for losses. For the 
region to be considered commonly altered across tumor groups it had to be present 
among the top 60 most frequent MCRs of alterations in at least three of the groups.  
 
To define potential group-specific alterations, significant differences in 
frequency of alterations between tumor subtypes were detected by Fisher Exact Test 
(FET) implemented in Nexus (with minimum recurrence differences between groups 
of 25% for gains and 35% for losses, and a p-value < 0.05). We also ran CGHtest (R 
package and www.few.vu.nl/~mavdwiel) to define regions exhibiting significant 
differences in frequency between tumor subtypes, using the chi-square test and false 
discovery rate (FDR) correction with 10,000 permutations, data simplification at the 
level of 0.01 and the “stepup” option. Regions defined to be significant (with FET and 
chi-square test, P<0.05) and an FDR < 0.2 (as defined by CGHtest) were listed as 
potentially group-specific. To further refine this list, our regions were compared with 
the regions defined in the TCGA ovarian study that characterized a series of 489 
mainly sporadic high-grade ovarian carcinomas (TCGA, 2011). Frequencies of regions 
of amplification, gain, loss and homozygous deletion in our list were compared to 
frequencies of "High Gains", "Low Gains", "Shallow deletions" and "Deep Deletions”, 
respectively, reported for the same chromosomal locations in the TCGA study (using 
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“wide peaks” ranges). Only candidate familial-specific regions from our list that were 
not defined as significant focal alterations in the TCGA series were considered to have 
some specificity for one of the familial groups. Similarly, regions significantly 
associated with sporadic tumors in our series that were also defined as significantly 
frequent in the TCGA study were considered to show some specificity for sporadic 
cases.  
 
2.4.3   Biological pathways altered by copy number changes 
 
In order to know about the specific pathways and processes that might be 
targeted by copy number alterations in each tumor group we performed a pathway 
enrichment analysis.  The analysis was performed using the lists of the genes 
encompassed within the minimal common regions of gains, losses, amplifications and 
homozygous deletions generated per each group, in the previous steps. Those lists 
were used to identify functions and processes enriched in copy number altered genes 
over the whole genome, in each tumor group. A comprehensive pathway enrichment 
analysis was performed integrating results from three publicly available databases: 
FatiGO (Babelomics v4), DAVID v6.7 (Database for Annotation, Visualization and 
Integrated Discovery) and Ingenuity Pathway Knowledge Base v9 (IPA). In case of IPA 
the direction of the alterations: either copy number increase (gains and 
amplifications) or copy number loss (deletions and homozygous deletions) was 
associated with each HUGO gene identifier. Only pathways defined to be significantly 
altered (P < 0.05) (enriched in gained and lost genes) by at least two different tools 
with at least one significant after correction for multiple testing (FDR<0.05) were 
considered. 
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2.4.4  Unsupervised analysis 
 
 
WECCA (Weighted Clustering of Called aCGH Data) R package (Van Wieringen 
et al, 2008) was used for unsupervised hierarchical clustering (total linkage and 
overall similarity algorithms) and generation of the heatmaps for called aCGH data. 
The maximum pairwise symmetrized Kullback Leibler divergence score (Tumminello 
et al, 2007) was used to define regions that best distinguished rendered clusters. 
Regions with the highest scores (≥1.5 for carcinomas; ≥3 for type II tumors) were 
defined as the ones differentiating clusters the best. Their exact location was defined 
based on GRCh37/hg19 assembly. The CGHtest (R package and 
www.few.vu.nl/~mavdwiel) was used to determine whether the selected regions 
were significantly differently represented between clusters after the Benjamini–
Hochberg FDR correction (with 10,000 permutations and the step-up procedure) that 
accounted for multiple testing. An FDR less than 0.01 was considered statistically 
significant.  
 
2.5 ASSOCIATION OF DEFINED REGIONS WITH SURVIVAL 
 
Defined regions were evaluated for their associated with overall and 
progression free survival using multivariate Cox regression model with forward 
conditional method in which all the tested regions were included together with all the 
confounding factors significant in the series (P<0.05): FIGO stage, and residual tumor. 
Final estimation of Hazard Ratios and P-values of the significant regions was 
calculated in the Cox regression model adjusted for two significant cofactors (FIGO 
stage, and residual tumor).  
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2.6 VALIDATION OF THE PROGNOSTIC VALUE OF 6q24-q26 
DELETION  
 
2.6.1 Validation in an independent series of tumors by Fluorescence 
in situ Hybridization (FISH) 
 
Fluorescence in situ hybridization was carried out in the Molecular 
Cytogentics Group (CNIO) using an independent series of 103 EOCs included in TMAs 
described in the Patients and Tumors section. Thirty-five additional tumors from the 
discovery series were analyzed to technically confirm aCGH data. 
FISH analysis was performed according to Vysis' protocol (Vysis, Downers 
Grove, IL, USA) with slight modifications (Moreno-Bueno et al, 2003). In brief, the test 
probe, composed of three BAC clones: RP11-608N7, RP11-68I24, RP11-100N9 
mapping to the 6q25.1 region (157099063-157530401) was labeled by nick 
translation with dUTP-SpectrumOrange (Abbott Molecular, IL, USA). Similarly two 
BACs: RP11-410B13 and RP11-107P14 targeting 6p21 (43490072-43543812) were 
labeled with dUTP-SpectrumGreen (Abbott Molecular, IL, USA) and used as reference 
for 6q deletion.  
The BACs were obtained from BACPAC Resource Center (BPRC) at the 
Children's Hospital Oakland Research Institute (Oakland, CA). The probes were 
blocked with Cot-1 Human DNA (Roche Diagnostics GmbH, Mannheim, Germany) to 
suppress repetitive sequences. Probes specificity was confirmed on normal 
peripheral blood metaphase cells.  
Paraffinated tissue slides were deparaffinated and boiled in a pressure 
cooker with 0.5 mM EDTA (pH 8.0) for 10 minutes and incubated with pepsin at 37°C 
for 21 minutes and dehydrated. The probe was first denatured at 96°C for 5 minutes 
and hybridized overnight at 37°C in a humid chamber. After posthybridization 
washes, the tissue samples were counterstained with DAPI VECTASHIELD solution 
(Vector Laboratories Inc., Burlingame, CA, USA) for chromatin counterstaining. Cell 
images were captured using an Olympus BX61 microscope with a 100×/1.30 NA oil 
objective and a cooled charge-coupled device camera (CoolSNAP ES; Photometrics) 
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connected to a computer running the CytoVision Image Analysis System (Applied 
Imaging, Newcastle, UK). 
The FISH analysis was performed by two investigators who had no prior 
knowledge of the genetic, clinical, or immunohistochemical features of the tumors. On 
average 5 (3-7) high-power fields with well defined-nuclei were analyzed per each 
sample (always in duplicates). Deletion was considered as positive, when at least 100 
cells/per tissue core showed one red signal less than green in the same nuclei. The 
deletion status in the tumors was then analyzed for association with patient´s 
outcome.  
 
2.6.2 Validation using data from TCGA ovarian study 
 
To validate the association of the 6q24.2-q26 deletion with patients outcome  
data for 411 HGSOCs from the TCGA ovarian cancer study (TCGA, 2011) was used.  
Normalized log2 ratios from 1M Agilent Sure Print Human Microarray platform were 
downloaded from TCGA website (https://tcga-data.nci.nih.gov/tcga/ 
dataAccessMatrix.htm) and subjected to the segmentation and calling (in the 
Structural Computational Biology Group) using the algorithms applied in the 
discovery series. Tumors were considered deletion-positive if at least 90% of the 
defined region (6q24.2-q26, 145,593,087-162,867,181) was lost. Deletion status was 
subsequently analyzed for associations with patients’ survival data (provided by 
TCGA).   
 
2.6.3 Validation at the global gene expression level   
 
The association of the 6q24-q26 deletion with survival was validated at the 
gene expression level using KM-plotter (Gyorffy et al, 2012) with the JetSet probset 
(Li et al, 2011). The KM-plotter is an online tool that allows the assessment of the 
prognostic value of the expression levels of microarray-quantified genes in ovarian 
cancer patients. The current database is set up using gene expression data and 
survival information of 1436 ovarian cancer patients downloaded from Gene 
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Expression Omnibus and The Cancer Genome Atlas (10 different datasets). The mean 
expression of the genes from the 6q24-q26 region was used and the data was 
dichotomized at the automatically selected best fitted cut-off into higher and lower 
expressing groups. Kaplan–Meier and log-rank test were used to characterize the 
distribution and estimate the outcomes. In addition Cox proportional hazard model 
was used to estimate the hazard ratios and 95% Confidence Intervals. The association 
with overall survival was assessed in all 1436 EOC with available OS data and was 
further confirmed in 799 HGSOCs (grade3) and in 675 high FIGO stage (III and IV) 
HGSOCs tumors alone.  
 
2.6.4 Definition of candidate genes at the 6q24-q26  
 
In order to propose individual candidate genes that might explain the 
observed association with patient survival, we first identified those genes in the 
6q24-26 region whose loss had an impact on expression. To address that we used 232 
tumors from TCGA ovarian study for whose copy number and expression data were 
available and assessed a total of 81 genes localized at 6q24.2-q26 for whom RNAseq 
data (RPKM) was available. The Wilcoxon rank test was used to compare the 
expression values of each gene between tumors with normal copy number status and 
tumors with genomic loss at each locus. Significant genes were then evaluated for 
potential association between their expression levels and patient survival. Before 
running survival analysis, RPKM values were normalized, by subtracting the mean of 
all samples and dividing by the standard deviation, in order to allow a direct 
comparison of hazard ratios between genes.  
 Next, the rescaled gene expression values for each of 296 HGSOCs from TCGA 
study (for whom clinical and RPKM data were available)  were included as an 
explanatory variable in Cox regression models, together with cofactors significantly 
associated with survival in the series (FIGO stage, age of diagnosis and BRCA 
mutation status).  
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2.7 STATISTICAL ANALYSES 
 
Statistical analyses were performed using SPSS 17.0 (SPSS Inc., Chicago, IL). 
Comparison of continuous variables was assessed using a two-tailed Student’s t-test 
for variables with approximate normal distribution (as determined by Kolmogorov-
Smirnov test), or by Mann-Whitney test otherwise. For categorical data (FIGO stage, 
tumor histology, grade, BRCA1/2 mutation status, and some IHC markers) Pearson´s 
Chi-squared Test or Fisher Exact Test was applied (in case of expected values less 
than 5). All tests were two-sided and P-value<0.05 was considered statistically 
significant. Overall survival (OS) and progression-free survival (PFS) were defined as 
specified in the “Patients´ clinical data” section (1.1.2).    
 
2.7.1 Survival analysis 
 
Estimation of survival time distribution was performed using Kaplan-Meier 
method and differences between survival curves were assessed for statistical 
significance with log-rank test, if the proportional hazard assumption was valid or 
Gehan–Breslow–Wilcoxon test otherwise. To adjust for other prognostic factors, 
potentially acting as confounding variables for each tumor series we created a 
multivariate Cox proportional hazards regression model including all possibly 
confounding variables: FIGO stage, residual tumor, age of diagnosis, BRCA mutation 
status, grade, histological type. In the final model, with tested variable, all covariables 
with P-values<0.05 were included. The prognostic value of 6q24-26 deletion was 
tested (in discovery and validation sets) by comparing patients positive for the 
deletion (having at least 90% of the region lost) versus all the others. 
 
 All statistical tests were two-sided and nominal P-values less than 0.05 were 
considered statistically significant. 
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1 CLINICO-HISTOPATHOLOGICAL CHARACTERISTICS OF THE 
FAMILIAL OVARIAN TUMOR SERIES   
 
Most of our familial series was represented by epithelial ovarian carcinomas, 
however in the series were also 4 borderline entitles, all of which belonged to BRCAX 
group. The rest of the carcinomas were mainly represented by high-grade serous 
tumors, however the histopathological features, like histotype and FIGO stage 
differed between the BRCA1/2- mutation carriers and BRCAX group. Most of the 
mutation carriers were of serous type (BRCA1, 90%; BRCA2, 100%) and of high FIGO 
stage (FIGO III; BRCA1, 57%; BRCA2, 67%) (Table 4). Two BRCA1 cases were 
classified as low grade-endometrioid and one as clear cell but none of the carriers 
were classified as mucinous or undifferentiated. In contrast, BRCAX group was more 
heterogeneous and presented a wider range of histological subtypes. Also a higher 
percentage of BRCAX tumors were diagnosed at early stage compared to carriers 
(FIGO=I; BRCAX, 31%; BRCA1, 5%; BRCA2, none) (Table 4). As expected, hereditary 
patients were diagnosed at a significantly younger age than sporadic ones (51 v 62 
yrs, p=0.001) with BRCA2 having the highest age of onset among all hereditary cases, 
and that was only marginally different than of that from sporadic cases (55 vs 62 yrs, 
P=0.06). 
 
As specified in Material and Methods a subgroup of tumors within the type II 
carcinomas was defined with high grade serous carcinomas, to allow for comparisons 
between more homogenous groups. This subgroup of familial carcinomas was 
enriched (although not significantly) in BRCA1/2 mutation carriers, compared to the 
whole series of carcinomas (type II, 14/22, 64%; whole series 27/53, 51%). Also 
within this more homogeneous set of tumors the differences regarding age of 
diagnosis are more distinguishable. More details about patients’ and tumors’ 
characteristics are summarized in Table 4.  
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2 GENOMIC INSTABILITY IN FAMILIAL AND SPORADIC EOC 
 
2.1 GLOBAL PATERN OF GENOMIC INSTABILITY IN EOC 
 
To reveal potential general differences in the rate and pattern of genomic 
instability between familial and sporadic EOCs, genomic alterations were first 
visualized by generating frequency plots. These plots display DNA copy number gains 
and losses in each chromosomal location across the genome (Figure 6).  
 
Overall the genomic instability level was high in all the EOC groups and the 
general pattern of alterations was not substantially different between familial (all 
subtypes) and sporadic tumors. In general most frequently lost and gained regions 
were common to both tumor groups (Figure 6-II and 6-III).  
 
Figure 6. Frequency plots of copy number gains (in green) and losses (in red) defined in all 
carcinomas and subgroups. The proportion of tumors with gained/lost regions is plotted on the y-
axis versus genomic location on the x-axis. Common recurrently altered regions across all four 
subgroups or present in >55% of the whole series are marked with black arrows on the general plot 
(for all series), while group-specific regions identified for sporadic, BRCA1 and BRCAX tumors are 
identified on the corresponding plots with blue arrows. Simplified chromosomal locations are given 
next to the arrows (using the same color code). 
 
Likewise, there were no significant differences between familial and sporadic 
tumors regarding the average total number of alterations and the average total length 
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of genome altered per tumor considering all carcinomas and the subgroup of type II 
neoplasms (Table 5). Both, familial and sporadic carcinomas showed very unstable 
genomic profiles with an average fraction of haploid genome altered of 27.9% 
(893Mb) and 28.75% (921Mb), respectively (Table 5). Group of type II carcinomas 
showed an average of more than 60 aberrations per tumor that involved more than 
1Gb of the altered genome (Table 5).  
Despite this general similarity, a separate analysis of gains and losses and 
stratification of familial tumors according to their BRCA1/2 mutation status revealed 
some differences. 
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2.2 NUMBER OF DNA COPY NUMBER CHANGES 
 
BRCA1 and BRCA2 tumors showed greater average number of losses and 
homozygous deletions (HD) than sporadic or BRCAX tumors. In contrast, sporadic 
cases presented the highest average number of gains and amplifications of all tumor 
subtypes (Figure 7A) (Table 5). A similar pattern was observed when only group of 
type II tumors was considered (Figure 7B and Table 5).  
 
Comparisons between number of gains versus number of losses performed 
within each tumor subtype revealed a similar average number of both events in 
sporadic tumors (25.7 v. 25.6, respectively). In familial cases, however, the average 
number of losses was 1.4 times greater than the average number of gains, with 
differences mostly attributed to BRCA1 (29.6 losses v. 21.7 gains, P=0.02) and BRCA2 
tumors (32.7 losses v. 14.5 gains, P =0.009) (Figure 7C and Table 5). This pattern was 
also observed in the subgroup of type II tumors, with significant and borderline 
significant differences between numbers of gains and losses in BRCA2 and BRCA1 
tumors, respectively (Figure 7D and Table 5). 
 
 
2.3 LENGTH OF GENOME ALTERED BY DNA COPY NUMBER 
CHANGES 
 
In agreement with the analysis of the number of alterations, we found that 
BRCA1 and BRCA2 tumors presented a significantly higher average length of genome 
altered by DNA losses when compared to sporadic or BRCAX cases (Figure 7E and 
Table 5). BRCAX tumors showed the lowest average length of genome altered by 
losses. This pattern was partially maintained in the subgroup of type II carcinomas, 
with significant differences between BRCAX and BRCA2 tumors (Figure 7F and Table 
5). Sporadic cases displayed more genome affected by copy number gains than 
familial tumors (358 v. 298 Mb) showing even larger difference in a subgroup of type 
II carcinomas although differences did not reach statistical significance.   
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Figure 7. Average number (A-D) and length (E-H) of copy number alterations in different groups of ovarian 
carcinomas (A, C, E, G) and type II carcinomas (B, D, F, H). Significant differences in number and length of 
alterations between (A-B, E, F) and within (C, D, G, H) tumor groups are indicated with *(p<0.05) or  
** (p<0.01). Error bars represent 95% Confidence Intervals.  
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Interestingly, in all tumor subtypes, including sporadic carcinomas, which 
showed a similar average number of both types of alterations, more genetic material 
was lost than gained (Figure 7G-H and Table 5). In BRCA1 and BRCA2 tumors the 
average length of lost genome was 2.1 and 3.8-fold greater than the length of gained 
material, respectively. In sporadic and BRCAX tumors differences were less marked 
(1.6-fold in both) (Figure 7G and Table 5). Differences between length of genome 
gained and lost per tumor were statistically significant in all familial tumors (BRCA1, 
BRCA2 and BRCAX), while only a trend was observed in sporadic cases (P=0.09). In 
the subgroup of type II tumors only differences in BRCA1/2 carriers remained 
significant (P<0.001) (Figure 7H and Table 5). 
 
 
2.4 MCRS OF DNA COPY NUMBER CHANGES DEFINED IN EACH 
TUMOR GROUP 
 
In order to define the most commonly altered copy number changes in each 
tumor group we defined minimal common regions (MCRs) gained in more than 25% 
or lost in more 35% of the group as shown in the Supplementary Table 2 and 
3,respectively. These regions served to identify the alterations shared between 
different tumor groups and also to define those potentially specific to each group.  
 
2.5 DNA COPY NUMBER CHANGES SHARED ACROSS TUMOR 
GROUPS 
 
To determine DNA copy number alterations that might be fundamental for the 
development and progression of ovarian carcinomas regardless their BRCA1/2 
mutation status, we sought to define frequently altered regions in all tumor groups.  
 
A summary of common gains and losses identified as recurrent in at least three 
of the analyzed tumors subtypes (BRCA1, BRCA2, BRCAX and sporadic) is shown in 
Table 6. Regions recurrently gained in the all four tumors subtypes were 6p25.3, 
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8q24.2-q24.3, and 12p13.33-p13.32, and regions exhibiting the highest frequencies 
were 3q26.2 and 8q24.2-q24.3 (Figure 6-I and Table 6). These regions and others 
defined as recurrently gained included from 1 up to 45 genes and spanned well 
known or potential oncogenes such as MECOM, PIK3CA, FOXQ1, MYC, CCND2 and 
CANT1.  
 
Regions recurrently lost in all four subgroups were defined at 9p24.3, 9p21.3, 
17q11.2-q12, 22q12.3, 22q13.1 and 22q13.31-q13.33. Alterations with the highest 
incidence were found at 8p23.3-p23.1 and 17p13.3-p11.2 (Figure 6-I and Table 6). 
Many of these deleted regions and the others qualifying as recurrent across tumor 
subtypes encompassed tumor suppressors previously linked to ovarian 
carcinogenesis (e.g. MCPH1, CDKN2A, CDKN2B and NF1). However, other regions 
pointed to less well characterized suppressors not previously associated with ovarian 
cancer (e.g. FANCC, TSC1, CREBBP, CDH11 and EDA2R).  
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2.6 GROUP-SPECIFIC DNA COPY NUMBER CHANGES  
 
Besides many similarities observed in the pattern of genomic instability 
between familial and sporadic tumors, some of the alterations were shown to be 
more associated with particular tumor type. The group-specific alterations were 
defined based on significant differences in the frequency of copy number alterations 
between two tumor groups using Fisher's Exact Test (FET). Preselected group-
specific alterations (P<0.05 and FDR<0.02) were further refined by comparison to the 
regions defined in 489 HG-SOC from TCGA ovarian study (TCGA, 2011) (Table 7).  
 
Since BRCA1/2 mutation carriers presented the largest amount of genome lost, 
alterations of this type were also the most frequent among the ones defined as 
specific for this group. Among the lost regions significantly the most frequently found 
in BRCA1 than in sporadic tumors were: 4q32.3-q34.1, 6q22.3-q26 or 12q21.2-q23.2 
spanning genes of tumor suppressive or potential suppressive function such as 
TNFAIP3, PERP or PLAGL1 (Table 7). 
 
Due to high variability of BRCAX tumors, regarding their grade and histological 
subtype and also lower overall genomic instability rate, specific regions associated 
with these tumors were difficult to distinguish. However, gains at 6p12.3-p11.2 and 
gains spanning chromosome 10 (10p14-p13, 10p11.23-p11.21, 10q22.1-q22.2) were 
significantly more frequent in this tumor group when compared to BRCA1 tumors 
(Figure 6-IV, Table 7). In particular, copy number gain at 10q22.1-q22.2 was identified 
exclusively in the BRCAX tumors. Further indication, that these alterations might be 
associated specifically with these tumors was revealed when more homogenous 
subgroup of high-grade type II BRCAX cases was considered. Then, exactly the same 
alterations at 10p and 10q were found to be significantly more frequent (by more 
than 45%) in BRCAX cases (in comparison to BRCA1 cases, p= 0.017 for gains at p 
arm and p=0.026 for gains at q arm at chromosome 10). 
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Among the alterations more significantly represented in sporadic cases we 
only identified changes that involved gain of genomic material. Gains at 2p23.3, 
12p11.22 and 19q12-q13.11 were significantly over-represented in sporadic tumors 
(Table 7), with the latter containing the CCNE1 gene that was also amplified in these 
tumors. 
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2.7 AMPLIFICATIONS AND HOMOZYGOUS DELETIONS  
2.7.1 High-level copy number gains 
 
The high resolution of our platform allowed us to identify focal high-amplitude 
copy number changes. The most frequent regions of amplification with their 
distributions across the groups of tumors are shown in Table 8 part A. Fifty-nine 
narrow amplifications (median length of 739Kb spanning on average 11 genes) were 
identified in at least 2 cases. In general amplifications tended to occur in the sites of 
frequent gains delineating potential driver oncogenes.  
 
The most frequent site of amplification is 8q22-ter with the highest peak at 
8q24.21-q24.3 containing MYC oncogene. Although this high copy number event was 
the most prevalent in familial tumors reaching 30% in BRCA1/2 mutation carriers, it 
was frequently gained in sporadic cases (in more than 60% of the cases). However, 
common region of amplification present in sporadic and at least two familial groups 
spanned more proximal parts of this chromosome, with 8q22.3 being the most 
frequent. This high copy number change encompassed only one gene – YWHAZ, that 
was previously implicated in, among others, breast and ovarian cancer (Bergamaschi 
et al, 2011; Li et al, 2010) (Table 8 part A and Table 9).  
 
Other prevalent (12%) site of common amplification was found at 11q13.1, 
spanning just 2 genes. One of whose was the Metastasis Associated Lung 
Adenocarcinoma Transcript 1, MALAT1, (Table 8 part A, Table 9) reported to be 
involved in cell growth, cell cycle progression and invasion of cervical (Guo et al, 
2010) and endometrial cancer (Yamada et al, 2006). 
 
Among amplifications, identified to be significantly more prevalent in one of 
the tumor groups, was 8q22.1 - found to be amplified exclusively in BRCA1 cases, in 
29% of this group. This high copy number gain consisted of only one gene - LAPTM4B, 
whose overexpression has been previously implicated to poor prognosis and 
metastasis of many gynecological carcinomas (Meng et al, 2010; Yin et al, 2011) 
(Table 8 part A and Table 9). 
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In addition, two amplified regions at chromosome 19 were found to be 
significantly more frequently altered in sporadic cases. In particular amplification of 
19q12 with CCNE1 indentified in 13% of those cases and gained in 47% of them. 
CCNE1 was also amplified in one BRCAX tumor, but it was not altered in any of 
BRCA1/2 mutation carriers (Table 8 part A). Similarly other amplifications spanning 
known oncogenes as: ERBB2 (17q21.32) or PIK3CA (3q26) were found exclusively in 
non-BRCA1/2 mutation carriers (Table 8 part A and Table 9). As previously 
mentioned sporadic cases showed more scattered pattern of high copy number 
alterations, while for familial cases, chromosome 8q was a main site of this type of 
aberrations.  
 
2.7.2 Homozygous deletions 
 
In addition to high copy number changes, 57 focal homozygous deletions (HD) 
(median length of 465 Kbp spanning 6 genes on average) were identified in at least 2 
samples (Table 8, part B).  
 
The most frequent (9%) and present in each tumor group HD was found at 
17q11.2 and contained only one gene, the known Ras pathway inhibitor  NF1. Also 
with the same frequency, 13q14.2 was homozygously deleted in sporadic and familial 
tumours and spanned only one gene, the crucial cell cycle regulator RB1. Other 
frequent HD common for sporadic and familial tumors was defined at 8p23.2-p23.1. 
One of the two genes located in this region was the early DNA-damage-response gene 
MCPH1, indicated to be involved in double strand DNA repair and recruitment of 
many important DDR proteins to the DNA damage sites, thus involved in maintenance 
of genomic stability (Lin et al, 2010). Another common HD found across familial and 
sporadic tumors was identified at the fragile site on chromosome 3 (3p14.2, FRA3B) 
that contained the known tumor suppressor- FHIT (Table 8 part B and Table 9).    
 
Deletions of 17q21.31 (with BRCA1 gene) were more frequent in BRCA1/2 
mutation carriers than in BRCAX and sporadic tumors (Supplementary Table 3). The 
MCR of loss at this region (17q21-q23) in BRCAX tumors did not include BRCA1 but 
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spanned the double-strand break repair protein BRIP1. The deletion of 13q13.1 (with 
BRCA2) was the most prevalent in tumors with BRCA2 mutation. 
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2.8 IMMUNOHISTOCHEMICAL VALIDATION OF aCGH RESULTS 
 
In order to validate our aCGH results we assessed the correlation between the 
assigned DNA copy number and the immunohistochemical expression of three genes 
targeted by high-amplitude events:  CDKN2A and RB1 located at homozygously 
deleted regions, and CCNE1 that was found amplified.  Immunohistochemical analysis 
showed complete lack or much lower expression of CDKN2A and RB1 in tumors with 
HD at these loci compared to the mean value of samples with a flat profile at 9p21.3 
and 13q14.2, respectively (Figure 8 A,B).  Tumors exhibiting CCNE1 amplification 
presented much higher expression compared to the mean value of tumors with 
normal DNA copy number at this locus (Figure 8 C). 
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Figure 8. Immunohistochemical results: expression of three markers evaluated in the tumors with high copy 
number changes identified by aCGH: homozygous deletion of CDKN2A (A); RB1 (B) and amplification of 
CCNE1 (C). From the left to the right: CGH profile at the loci affected by copy number changes with the 
chromosomic location on x-axis and corresponding log2ratios on the y-axis; expression of the IHC antibody in 
the same tumoral sample (8 x magnification) with corresponding 40 x magnification of the part of the tumor 
(arrows pointing to internal controls for homozygous deletions); the most right panel shows expression of 
given antibody in the control sample (at 8x and 40x magnification) representing mean expression of the 
samples with normal DNA copy number status at this loci. The corresponding expression levels of the three 
antibodies, are shown in the right down corner next to each sample. The integral control is either macrophage 
within tumoral mass (CDKN2A) or stained tumoral cell (RB1). 
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2.9 PATHWAYS OF BIOLOGICAL RELEVANCE  
 
To determine biological processes, which might be affected by copy number 
changes in each tumor group we performed pathway enrichment analysis using 
publicly available databases and the lists of genes identified within MCRs of gains, 
losses, amplifications and homozygous deletions per tumor group.  
 
As shown in Table 10 there were no striking differences in the pathways 
significantly enriched in the different tumor groups. Cell cycle regulation and 
checkpoint pathways were found significantly associated to all tumor groups. In 
addition immune response pathways typically altered in cancer like Jak-STAT and 
Toll-like receptor signaling were enriched in BRCA1 and sporadic tumors, as well as 
was PIK3/AKT-signaling that is commonly found activated in ovarian tumors. 
 
However, besides these similarities some pathways, like DNA repair through 
homologous recombination and Ras pathway were more frequently altered in BRCA1 
tumors. As expected, loss of BRCA1 function in DNA damage response was defined to 
be specifically associated with this tumor group (Table 10).  
 
 In sporadic series in addition to the pathways involved in immune response 
other activated (enriched in gained and amplified molecules) functions were related 
to oncogenic pathways (MAPK-, EGFR-, PDGF-, VEGF- and IGF1-signaling) suggesting 
their relevant role in the oncogenesis of sporadic tumors (Table 10). 
 
 High heterogeneity of BRCAX tumors together with their lower overall 
genomic instability lessened the chances of identifying many significantly enriched 
pathways. However cycle regulation and DNA replication-related pathways were 
identified as significantly enriched in this group (Table 10).  
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3 DNA COPY NUMBER-BASED UNSUPERVISED CLUSTERING OF 
EOCs 
 
3.1 FAMILIAL STATUS OF THE EOCs STRATIFIED BY DNA COPY 
NUMBER PROFILING  
 
In addition to systematic comparison of copy number alterations across 
different tumor subtypes, we also carried out unsupervised analysis of the aCGH data 
to unveil possible association between particular patterns of genomic changes and 
the sporadic or familial status of tumors (or specific familial subytpe, BRCA1/2/X).  
 
Unsupervised hierarchical clustering stratified our series of ovarian 
carcinomas into two main clusters (A and B) (Figure 9A). There were no significant 
differences found between tumors from both clusters (or from smaller subgroups) 
either according to their general familial or sporadic condition or according to their 
specific BRCA mutation status (Figure 9A). Similarly, unsupervised hierarchical 
clustering of the subgroup of type II tumors also rendered two clusters (IIA and IIB) 
without significant enrichment in tumors from particular BRCA subgroups (Figure 
9B). 
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Figure 9. DNA copy number-based unsupervised hierarchical clustering of 68 primary ovarian carcinomas (A) 
and 31 type II carcinomas (n=31) (B). Each column represents a tumor sample and each row corresponds to 
DNA copy number changes mapped according to chromosomal location. Colors correspond to different copy 
number categories: red, loss; green, gain; white, amplification; black, lack of copy number changes. 
Dendrogram highlights the division of the samples into two main clusters. Hereditary or sporadic condition of 
tumors, immunohistopathological features and the 6q deletion status are represented by color labels shown 
below the dendrogram.  
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3.2 IMMUNOHISTOPATHOLOGICAL CHARACTERIZATION OF EOC 
CLUSTERS DEFINED BY THEIR DNA COPY NUMBER PROFILES  
 
Since having or not BRCA1/2 mutation did not seem to stratify the tumors into 
groups of specific pattern of DNA copy number alterations, we sought to determine 
whether tumors that shared a similar genomic instability profile may share a 
distinctive and biologically meaningful pattern of immunohistopathological features.  
 
Cluster B, which comprised the most genomically unstable tumors, with higher 
number and length of alterations, was significantly enriched in high FIGO stage 
(P=0.03) and serous tumor type (versus all other subtypes, P=0.001). It was also 
characterized by higher proliferative rate (as measured by Ki-67 immunostaining) 
and increased expression of p53 and the antiapoptotic marker survivin (Figure 9A , 
Table 11).   
No more significant associations were found with any other of 27 
immunohistochemical markers (all the evaluated markers are listed in the 
Supplementary Table 4 and Supplementary Table 5). 
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When more homogenous group of type II carcinomas was considered, Cluster 
II-B, of more pronounced genomic loss, showed some evidence of higher expression 
of Progesterone Receptor (PR) (P=0.05) and survivin (P=0.06) (Table12). 
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3.3 DNA COPY NUMBER DEFINED GROUPS OF EOCs  
AND THEIR ASSOCIATION WITH PATIENTS’ SURVIVAL  
 
We further aimed to determine whether groups of ovarian tumors defined 
according to their copy number features differed in terms of patients’ prognosis.  
 
Univariate Cox regression analysis of clinicopathological variables confirmed 
the association of known prognostic factors, such as FIGO stage and status of 
debulking surgery with both overall survival (OS) and progression-free survival (PFS) 
(Table 13). Age, grade, histotype or BRCA mutation status did not show an association 
with survival in our series. Similarly, the DNA copy number-based defined clusters (A 
and B) were not significantly associated with survival in the univariate analysis. 
However, adjustment for significant cofactors (FIGO stage and debulking status) 
revealed an association of cluster B with better OS (HR=0.28, 95% CI:0.08-0.93; 
P=0.04) (Table 14).   
 
 
To further corroborate this result, the analysis was repeated within high FIGO 
stage carcinomas only, as these tumors represent the majority of the series and the 
association of cluster (B) with improved survival was found already in the univariate 
analysis (HR=0.29, 95%CI:0.09-0.93, P=0.028) (Figure 10A).  
  Results 
Page | 115  
 
 
 
Figure 10. Kaplan-Meier survival curves. Overall Survival of high FIGO stage EOCs patients from the 
discovery series according to (A) clusters defined by DNA copy number-based unsupervised analysis (log-
rank P=0.028) and (B) the presence of the 6q24.2-26 deletion (log-rank P=0.003). Validation of the 
association observed between the presence of the 6q24.2-26 deletion and improved overall survival in two 
independent series from (C) EOCs where the deletion was evaluated by Fluorescence in situ Hybridization 
(log-rank P=0.015) and (D)  HGSOC patients from the TCGA study (log-rank test P=0.002). Lower expression 
of the genes within 6q24.2-26 region predicts longer Overall Survival in (E) all 1436 EOCs (log-rank 
P=0.0002) and in (F) 799 HGSOC carcinomas (log-rank P=0.002), as shown using an online tool KM-plotter 
from publicly-available microarray data.(Gyorffy et al, 2012)  
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More importantly it remained significant on adjustment for debulking status 
(HR=0.27, 95%CI=0.08-0.94, Padj=0.04) (Table 14). To minimize the effect of death not 
due to ovarian cancer we confirmed the association after censoring all follow-up five 
years after diagnosis, both overall and for high FIGO stage carcinomas only (Table 14). 
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Considering type II tumors only, the association of  the more genomically 
unstable cluster II-B with better prognosis showed some, but weak evidence, in the 
univariate analysis (P=0.07) and after adjustment for debulking status in both OS and 
5-years survival (HR=0.09, 95%CI=0.01-1.13, Padj=0.06 and HR=0.10, 95%CI=0.01-
1.33, Padj=0.08, respectively)  (Table 14). 
 
3.4 EXPLAINING DIFFERENCES IN SURVIVAL OF PATIENTS FROM 
DIFFERENT CLUSTERS  
 
3.4.1 BRCA1/2 mutation status 
 
Due to the fact that ovarian cancer patients with germline BRCA1/2 mutations 
show improved survival rate (Alsop et al, 2012; Bolton et al, 2012; Pennington & 
Swisher, 2012) and considering that, although not significant, cluster B showed some 
enrichment in mutation carriers (Table 11), the association of the clusters with 
survival was adjusted also for this factor (in addition to FIGO and debulking status) 
even if BRCA condition was not significant in the univariate analysis performed in our 
series (Table 12), Nevertheless, the association remained statistically significant 
(HR=0.28, 95%CI:0.08-0.96, Padj =0.043) indicating that BRCA1/2 mutation status did 
not explain the better survival of patients from the higher genomic instability cluster. 
 
3.4.2 Genomic instability level  
 
In ovarian tumors and other neoplasms it has been shown that higher genomic 
instability is associated with worse prognosis (Carter et al, 2006; Choi et al, 2009; 
Cope et al, 2013; Walther et al, 2008). However, extreme genomic instability provides 
beyond particular level, no growth advantage for cancer cell viability and is 
deleterious for cell survival (Baumbusch et al, 2013; Birkbak et al, 2011; Roylance et 
al, 2011). Therefore, we hypothesized that this effect might explain the better 
outcome of the patients with tumors in the more genomically unstable clusters.  
In order to address this question we assessed the association with survival of 
genomic instability (GI), measured as the total length of altered genome, and included 
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as an explanatory variable dichotomised at the median, or categorized into quartiles. 
Patients with tumors with GI above the median had worse prognosis (HR=6.51, 
95%CI: 1.2 - 35.07, Padj=0.029) (Figure 11) and gradually increasing GI was also 
associated with worse outcome (HR=2.36 per quartile of GI, 95%CI: 1.17- 4.77, 
Padj=0.016),(Cope et al, 2013) suggesting that in our series extreme levels of GI do not 
hinder tumor development (Carter et al, 2006; Kronenwett et al, 2004; Walther et al, 
2008). Moreover, the association of cluster with survival was stronger after 
adjustment for this variable (HR=0.20, 95%CI: 0.056 – 0.75, Padj= 0.018). 
 
 
 
Figure 11. Kaplan-Meier survival plot for overall survival according to genomic instability (GI) level defined 
using median total length of the genome altered (log-rank P=0.004) 
 
 
3.4.3  Specific DNA copy number alterations 
 
After ruling out the level of genomic instability as a factor that may explain the 
differences in the survival between clusters, we hypothesized that specific copy 
number changes might explain the observed association.  
 
For this purpose we determined altered regions that significantly (FDR<0.01) 
differentiated clusters A and B (and clusters IIA and IIB) by calculating the maximum 
pairwise symmetrized Kullback Leibler divergence score for each chromosomal 
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region rendered in the clustering analysis (as described in Materials and Methods). 
Top scored regions, significantly differentiating clusters after FDR correction are 
shown in Table 15. All top regions were then tested for their association with overall 
survival using Kaplan-Meier estimates. 
 
Only one deletion at 6q24.2-6q26 (145,593,087-162,867,181), spanning 152 
genes, more predominant in cluster B (Table 15) was found to be significantly related 
to better outcome (HR=0.51, 95%CI: 0.2-1.29, P=0.028) (Figure 10B).  
This association remained significant after adjustment for FIGO stage and 
debulking status (HR=0.14, 95%CI=0.04-0.49, Padj =0.002) (Table 14) and on limiting 
the analysis to high FIGO stage tumors only (HR=0.13, 95%CI=0.04-0.48, Padj=0.002) 
(Table 14) and to HGOCs only (HR=0.17, 95%CI=0.04-0.72, Padj=0.016) (Table 14). 
The association was also maintained on additional adjustment for age, grade, and 
BRCA1/2 mutation status. Among the regions differentiating clusters IIA and IIB in 
the subgroup of type II tumors the same deleted region (6q25.1) characteristic for 
cluster II-B (Table 15), showed a tendency towards better prognosis (Padj=0.062). 
 
Among regions differentiating clusters II-A and II-B (type II tumors only) a 
deleted region in the same chromosomal location (6q25.1), characteristic of cluster 
II-B (Table 15) showed weak evidence of association with better prognosis in the 
univariate analysis (P=0.1) and after adjustment for debulking status (HR=0.09, 
95%CI=0.01-1.13, Padj =0.062).  
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4 PROGNOSTIC VALUE OF THE 6q24.2-q26 DELETION IN 
OVARIAN CANCER 
 
4.1 VALIDATION IN AN INDEPENDENT OVARIAN CANCER SERIES BY 
FISH ANALYSIS 
 
In order to validate our findings we performed FISH using a 6q25.1 probe 
(Figure 12) in an independent series of 103 EOCs of different histology that also 
included a subset of familial cases. Eighty-four tumors were successfully hybridized. 
The deletion was detected in 48% of successfully hybridized cases and was associated 
with significantly better overall survival (P=0.015) (Figure 10C). After adjusting for 
the only significant covariable (FIGO stage) in this series, the 6q deletion was 
confirmed to be an independent prognostic marker for overall survival (HR=0.38, 
95%CI=0.15-0.96, Padj=0.042). In addition, to acknowledge the atypical histological 
composition of this tumor series and different status of the residual disease the 
association was further proved on adjustment for histological type, tumor grade and 
debulking status (HR=0.25, 95%CI=0.065-0.96, Padj=0.045). The results were also 
consistent on adjusting for age, BRCA1/2 mutation status. 
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Figure 12. Evaluation of the 6q24.2-26 deletion by Fluorescence in situ Hybridization (FISH) on paraffin-
embedded tissue sections. Test (red) and reference (green) probes mapped to 6q25.1 and 6p21, respectively. 
Presence of one single red signal is indicated with an arrow. (A) Tumor from validation series showing 
deletion at 6q25.1. (B, C, D) Chromosome 6 array-CGH profiles (top panels) of tumors from the discovery 
series and corresponding FISH analysis (lower panels) confirming the presence of the deletion (B, C) and 
normal DNA copy number at this locus (D). Magnification: 100x  
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4.2 VALIDATION IN THE TCGA OVARIAN CANCER SERIES 
 
Since HGSOCs are the most common and lethal EOCs we aimed to further 
validate the association of the 6q24.2-q26 deletion with disease outcome  in this 
specific histotype by using 411 HGSOCs from the TCGA ovarian cancer study (TCGA, 
2011). Normalized log2 ratios from 1M Agilent Sure Print Human Microarray platform 
were downloaded from TCGA website (https://tcga-
data.nci.nih.gov/tcga/dataAccessMatrix.htm) and subjected to the segmentation and 
calling algorithms used in our discovery series (Materials and Methods). Tumors 
were considered deletion-positive if at least 90% of the defined region (6q24.2-q26, 
145,593,087-162,867,181) was lost. The deletion was associated with survival 
advantage in the univariate analysis (P=0.002) (Figure 10D) and, once adjusted for 
significant confounders (FIGO stage, BRCA1/2 mutation status, and age at diagnosis) 
(HR=0.67, 95%CI=0.48-0.93, Padj=0.019). Further adjustment for debulking status 
produced consistent results. The prognostic value of the marker was also confirmed 
for 5yr survival (HR=0.61, 95%CI=0.41-0.89, Padj=0.010).  
 
4.3 VALIDATION BY USING GLOBAL GENE EXPRESSION AT  
6q24.2-q26 AND A META ANALYSIS APPROACH 
 
Assuming that copy number status has an impact on the mRNA level we 
evaluated the prognostic value of the deletion at the gene expression level using KM-
plotter (Gyorffy et al, 2012), which integrates gene expression and clinical data from 
10 different data sets for 1436 EOCs patients (Materials and Methods). We found that 
low mean expression of the genes within 6q24.2-26 region was associated with 
longer OS in all 1436 EOCs patients (HR=1.32, 95%CI=1.14-1.53, log-rank P=0.0002) 
and on limiting the analysis to 799 HGSOCs (HR=1.35, 95%CI=1.11-1.64, log-rank 
P=0.002) (Figure 10E and Figure 10F, respectively) and to 675 high FIGO stage 
(III&IV) HGSOCs only (HR=1.31, 95%CI=1.04-1.64, log-rank P=0.02). The results were 
consistent once 5yrs follow up period was considered. In addition, to acknowledge 
the effect of confounding factors, the association was evaluated separately in the 
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stratified groups (optimally and suboptimally debulked tumors; high and low FIGO 
stage tumors) producing consistent results. 
 
4.4 DEFINITION OF CANDIDATE GENES EXPLAINING SURVIVAL 
ASSOCIATION  
 
Next, in order to propose individual candidate genes that might explain the 
observed association, we selected only those genes whose copy number status 
actually had an impact on the expression level. By using 232 tumors with accessible 
copy number and expression data from TCGA study we found that 76% of the 
examined genes in the region (62 out of 81 with available RNAseq data) were 
significantly down-regulated when lost (FDR<0.05) (Materials and Methods and 
Supplementary Figure 1).  Of these, multivariate Cox regression analysis identified 
four genes whose downregulation was significantly associated with better survival 
independently of known prognostic factors (FIGO stage, age at diagnosis, and 
BRCA1/2 mutation status) (Padj<0.05) and eight additional genes that showed 
borderline associations (Padj<0.1) (Materials and Methods and Table 16).  
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 Epithelial ovarian cancer is a very heterogeneous disease with many histological 
subtypes and classification criteria. It represents more a range of different diseases 
sharing an anatomical location (Prat, 2012b). Therefore, current efforts in the field 
pursue the stratification of EOCs into biologically meaningful groups that actually 
reflect different clinical behavior. As for other neoplasms the emphasis is now made 
on gaining knowledge about the molecular alterations that characterize the different 
groups of tumors, which ultimately might determine response to treatment and 
patients´ outcome.  
 
  So far few studies have specifically analyzed the DNA copy number changes that 
characterize the different groups of hereditary ovarian tumors (BRCA1, BRCA2 and 
BRCAX) or have compared these changes with those observed in sporadic cases 
(Israeli et al, 2003; Leunen et al, 2009; Patael-Karasik et al, 2000; Ramus et al, 2003; 
Zweemer et al, 2001). Moreover, the few studies conducted have yielded 
contradictory results, which might be due to limited number of tumors included 
(Israeli et al, 2003; Leunen et al, 2009; Patael-Karasik et al, 2000), the use of low 
resolution platforms (Patael-Karasik et al, 2000; Ramus et al, 2003),  the application 
of different algorithms or the dissimilar characteristics of the comparisons made 
(TCGA, 2011).  
 
 With these antecedents and given the recently confirmed relevance of copy 
number changes as drivers of ovarian oncogenesis (TCGA, 2011) and the growing 
clinical implications of the BRCA1/2 mutation status, we aimed to determine how 
hereditary and sporadic ovarian tumors relate to genomic instability and to define 
common and/or distinct events occurring in the genesis and evolution of these 
neoplasms.  In our study we tried to address some of the limitations of prior studies 
by using a high-resolution aCGH platform and separately considering copy number 
gains and losses. Also, in contrast to the majority of previous studies, we not only 
analyzed tumors from carriers of BRCA1/2 mutations, but also from non-BRCA1/2 
hereditary patients (BRCAX tumors) as these have been particularly poorly 
characterized.  
 
Discussion 
 
Page | 128  
 
1. HIGH SIMILARITY BETWEEN DNA COPY NUMBER PROFILES OF 
SPORADIC AND FAMILIAR EOC 
 
 Our findings indicate lack of substantial differences in the global pattern of DNA 
copy number changes between sporadic and familial EOCs. The general profile of 
genomic instability between those tumors was comparable as reflected by similar 
frequency plot overviews and similar total number and length of copy number 
alterations. Also this resemblance was illustrated by the existence of several shared 
regions found to be recurrently altered in each group of tumors. These common 
events point to the involvement of genes fundamental for ovarian carcinogenesis, 
selected throughout the evolution of the tumors and providing advantage to any 
cancer cell, independently of the existence of germinal mutations in the BRCA1/2 
genes.  
 
 Some of the possible candidates have been previously implicated in ovarian 
carcinogenesis such as PIK3CA, MECOM and MYC oncogenes, found within recurrently 
amplified and gained regions or NF1 and RB1 tumor suppressors, defined within 
commonly deleted genomic regions. In addition we also defined other less 
characterized genes, whose gain of function (CDH12, FOXQ1, TXNDC5, CCND2, FOXJ1) 
and/or abrogation (FANCC, TSC1, CREBBP, CDH11, EDA2R) might be crucial for 
ovarian cancer development and/or progression. Exploration of the therapeutic 
opportunities provided by these targets, to which a majority of tumors are likely to be 
addicted, is an attractive possibility.  For instance, it has been suggested that 
modulation of cellular activities of the forkhead transcription factor FOXQ1 may have 
an application in cancer therapy, since its inhibition blocks epithelial to mesenchymal 
transition and results in cancer cell sensitization to a variety of chemotherapeutic 
agents (Qiao et al, 2011). Therapeutic approaches targeting cyclin D gene have also 
been explored (Dong et al, 2010; Tiedemann et al, 2008) and might be applicable to 
EOCs presenting aberrant CCND2 expression due to DNA-copy number gains.  
Likewise, m-TORC1-directed therapies may be more effective in cancer patients, 
whose tumors present TSC1 (tuberous sclerosis complex 1) genomic losses as it has 
been proposed for patients whose tumor harbor TSC1 somatic mutations (Iyer et al, 
2012).  
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Also exemplifying the absence of marked differences in the profile of genomic 
changes of carriers and non-carriers of BRCA1/2 mutations, unsupervised 
hierarchical clustering did not stratify tumors according to their familial or sporadic 
condition, nor did it according to their BRCA1/2 mutation status. These findings are in 
contrast to what has been observed in familial BRCA1 and BRCA2 breast tumors, 
which show an association with particular molecular subtypes (defined with 
expression arrays) and specific patterns of copy number changes (Bergamaschi et al, 
2006; Jonsson et al, 2005; Melchor et al, 2008; Stefansson et al, 2009). Lack of 
segregation of ovarian tumors from carriers and non-carriers of BRCA1/2 germline 
mutations, based on their genomic instability pattern, would support a model 
according to which homologous recombination (HR) deficiency, arising through 
distinct mechanisms including germline, but also somatic inactivation of the BRCA1/2 
genes, methylation of BRCA1 or other members of the pathway, and EMSY 
amplification, is not only a frequent event explaining about  50% of high-grade serous 
ovarian carcinomas (Bowtell, 2010; TCGA, 2011), but also an event occurring in the 
initial phases of tumor growth. Such events mimicking biologic behavior of BRCA1/2 
deficient tumors and their phenotypic characteristics has been termed “BRCAness”. 
This notion was started in 1996 following the few studies on inactivation of BRCA1/2 
genes in sporadic ovarian tumors, pointing to their resemblance of BRCA-related 
tumors (Esteller et al, 2000; Foster et al, 1996; Geisler et al, 2002). 
  
 Although our results support the hypothesis only at the genomic level, other 
evidence from gene expression profiling of sporadic and familial tumors also 
indicates lack of consistent separation of high grade ovarian carcinomas according to 
BRCA1/2 status (George et al, 2013a; Pradhan et al, 2010) 
 
2. EXTENSIVE GENOMIC LOSS IN BRCA1/2 EOC 
 
Interestingly, despite this similarity between sporadic and hereditary tumors, 
some differences in the overall degree of genomic instability were revealed when 
gains and losses were analyzed separately. Greater contribution of losses than gains 
was observed in all tumor subtypes, however the extent of this phenomenon was 
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more prominent in carriers of BRCA1 and BRCA2 mutations, both in global terms 
(comparison of losses made across tumor subtypes) and relative to the number of 
gains (comparison within each tumor subtype).  
Some prior studies, including the most comprehensive one conducted by the 
TCGA Research network in high-grade serous ovarian carcinomas  reported no 
differences in the global degree of instability between tumors with BRCA1/2 
inactivating events and those with functional BRCA1/2 genes (Ramus et al, 2003; 
TCGA, 2011). However, no distinction was made between gains and losses, and only 
comparison of total changes was conducted. Earlier studies already suggested the 
relevance of loss of heterozygosity (LOH) in ovarian tumors from BRCA1 and BRCA2 
mutation carriers (Leunen et al, 2009; Walsh et al, 2008; Wang et al, 2012a), but 
included very few familial cases (Leunen et al, 2009; Walsh et al, 2008) or used low-
resolution platforms (Leunen et al, 2009). Our results derived from analysis made 
across tumor types, within each tumor subgroup and particularly when taking into 
account only a subgroup of  high-grade type II tumors highlight the relevance of 
genomic loss in BRCA1 and BRCA2 tumors, a phenomenon that would not merely 
reflect differences related to the higher grade or more prevalent serous histotype of 
those tumors.  
Our findings suggest that in the oncogenesis of ovarian tumors, and in 
particular of hereditary BRCA1 and BRCA2 carcinomas, loss of function of tumor 
suppressors might be under greater selection pressure than gain of function of proto-
oncogenes at least through DNA copy number-related mechanisms.  In fact, a gain of 
function of proto-oncogenes (MAPK, EGFR, PDGF, VEGF, and IGF1) in sporadic cases 
rather than in BRCA1 tumors was supported by the pathway enrichment analysis.  
However, despite a potential selection pressure for loss events in tumors from 
carriers we did not found enrichment of particular suppressor pathways in the 
BRCA1 associated tumors. This fact, and the lack of clear segregation of BRCA1 and 
BRCA2 tumors in the unsupervised analysis would suggest that most of the genomic 
loss in carriers would not involve a consistent set of specific critical regions (or 
specific suppressor genes) recurrently selected during evolution of these particular 
tumors.  Alternatively, greater involvement of loss events in ovarian tumors might be 
related to impairment of HR function, with grosser effects in BRCA1 and BRCA2 
 Discussion 
  
Page | 131  
 
tumors due to their central role in the pathway.  It should be noted that the results 
derived from the pathway enrichment assessment would be limited by the fact that 
the analysis was performed entirely based on genes identified to be altered only at 
the DNA copy number level without further integration with gene expression data. 
 
3. DNA COPY NUMBER PROFILES OF BRCAX TUMORS RESEMBLE 
SPORADIC MORE THAN OTHER FAMILIAL CASES  
 
Interestingly, in our study, that included a representative group of familial 
BRCAX cases, we found that this group shares more similarities with sporadic cases 
than with BRCA1 and BRCA2 tumors. While BRCA1 and BRCA2 were characterized by 
extensive genomic loss, BRCAX tumors presented the lowest total number of 
alterations overall and in particular of losses. Also, the greater involvement of losses 
compared to gains in tumor from carriers was less marked in BRCAX tumors and 
similar to that observed in sporadic cases.  
 
This would be consistent with the fact that the predominant role of genomic 
losses in EOCs might be to a great extent determined by HR defects and in particular 
with this feature being more prominent due to specific HR impairment by BRCA1 and 
BRCA2 dysfunctions. Up to 50% of sporadic cases are expected to show HR 
impairment through different mechanisms that include BRCA1/2 germline mutations 
(despite lack of familial history), somatic mutations and epigenetic silencing and also 
through alterations in other genes of the pathway (Bowtell, 2010; TCGA, 2011). In 
BRCAX tumors the presence of BRCA1 and BRCA2 germline mutations has been ruled 
out through genetic testing and this, may at least partly account for the lower rate of 
losses observed in this group of tumors. It is possible that these tumors may have 
germline HR disruption by loss of function of other genes involved in the pathway 
(such as RAD51D, RAD51C, BRIP1, CHEK2 or BARD1), loss of which may have less 
prominent impact on the genomic instability level. However alterations in these 
genes may explain only a low percentage of familiar cases (about 6% altogether) 
(Pennington et al, 2013). Also, the lower rate of losses in BRCAX cases might suggest 
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that majority of unknown susceptibility genes responsible for the ovarian cancer risk 
in the BRCAX families might belong to pathways different than HR.  
 
4. GROUP-SPECIFIC COPY NUMBER ALTERATIONS AS POTENTIAL 
BIOMARKERS OF BRCAness 
 
Although lack of clear segregation of hereditary and sporadic tumors in the 
unsupervised analysis indicates that there is not a clear pattern of critical regions 
consistently related to each subgroup of tumors, we were able to define some 
alterations potentially associated with BRCA1 and sporadic tumors. The individual 
regions with significantly different frequency in the different groups of tumors might 
reflect an accumulation of few selected genomic events acquired during development 
of tumors of a particular genetic background.  
 
BRCA1 associated regions are of particular interest, as might be pointing to 
genes whose loss or gain is selectively required to permit cell growth of the highly 
genomically unstable-BRCA1 defective cells.  Importantly they may serve as 
biomarkers to identify tumors with BRCAness (Rigakos & Razis, 2012; Wysham et al, 
2012), which has important implications in the clinical setting given the enhanced 
response to PARP inhibitors shown by EOCs from BRCA1 and BRCA2 mutations 
carriers (Ratner et al, 2012). In our series we reported that losses at 4q32.1-q35.2, 
13q13.3-q14.3, 17q11.1-q11.2, 17q12, 17q21.32-q21.33, 17q24.3-q25.1 and 
22q13.31 are more specifically related to BRCA1 cases and these alterations were 
also previously shown to be associated with this tumor group (Domanska et al, 2010; 
Ramus et al, 2003; Zweemer et al, 2001).  
 
In contrast much fewer regions were reported to be specifically associated with 
sporadic cases, most of them occurred at chromosome 19 and consisted of copy 
number gains or amplifications. Reassuringly, the largest so far ovarian cancer study 
of TCGA (TCGA, 2011) reported that amplifications of two of these regions, 19p13.13 
and 19q12, the latest encompassing  CCNE1, were the only ones significantly enriched 
in high-grade serous sporadic EOCs. This finding reinforces the proposed role for 
CCNE1 and of other proteins implicated in cell cycle progression as important 
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contributors to ovarian carcinogenesis in tumors with intact BRCA1/2 function 
(Berns & Bowtell, 2012; Bowtell, 2010; TCGA, 2011). 
 
Given the fact that patients with BRCA1/2-mutated ovarian tumors present 
relatively uniform behavior with high overall response rates to first-line platinum-
based therapy  (Boyd et al, 2000; Vencken et al, 2011), long disease-free intervals, 
and improved overall survival rates (Alsop et al, 2012; Bolton et al, 2012; Yang et al, 
2011), it is of a great importance to identify markers that help to identify BRCA-
related patients, who present better response to standard treatment regimes and are 
more likely to benefit from the treatment with PARP inhibitors. Screening for somatic 
and/or germline mutations to identify those patients is impractical for large 
populations and also non informative for other kinds of defects in the HR pathway 
that can lead to BRCAness.  
Although the early attempts to identify BRCAness features, mainly based on 
gene expression profiling in BRCA1/2 deficient and proficient tumors, (Jazaeri et al, 
2002; Konstantinopoulos et al, 2010) led to define a gene signature that was 
successfully predicting BRCA-like phenotype, it did not present further clinical utility. 
In this study, we propose several DNA copy number regions, specifically associated 
with BRCA1 mutation carriers that may be used to guide the selection of BRCA-related 
patients. In addition, in the light of recent findings reporting mutual exclusivity 
between BRCA1/2 impairment and CCNE1 amplification (Bowtell, 2010; TCGA, 2011), 
the predictive value of each of the identified regions, together with the absence of 
mutually exclusive ones, may help to develop a scoring system, that would more 
accurately predict a BRCAness phenotype. The big advantage of such DNA-based 
markers is the fact that they can be easily analyzed on paraffin sections by FISH, 
therefore being particularly suitable for routine clinical applications. In addition, the 
greater rate of copy number losses that has been found specifically associated with 
BRCA1 and BRCA2 mutation carriers may also serve as a marker itself.  
The usefulness and robustness of these particular DNA copy number changes 
and of the rate of genomic loss in defining the BRCA1/2 phenotype need to be 
validated in larger cohorts and prospective studies. However, in addition to other 
approaches of feasible implementation in the clinical setting, such as the sequencing 
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of a reduced panel of informative genes (ie. DNA repair, chromatin remodeling and 
DNA cohesion related genes) (Bajrami et al, 2013) copy-number changes might 
demonstrate utility in predicting the BRCA-like phenotype in EOCs.  
 
5. DNA COPY NUMBER PROFILES DIFFERENTIATES EOCs INTO 
GROUPS OF DIFFERENT IMMUNOHISTOPATHOLIGICAL AND 
CLINICAL FEATURES  
 
In addition to gain insight into the differences and similarities of familial and 
sporadic EOCs, we were interested in defining novel prognostic and predictive 
biomarkers in epithelial ovarian cancer. Since this  neoplasm  is the most lethal 
gynecological malignancy (Ferlay J et al, 2013)  the identification of novel molecular 
markers that may explain the different clinical behavior of EOC patients is of critical 
importance.  In this context we have investigated whether stratification of EOCs on 
the basis of DNA copy number may delineate novel categories of tumors with 
different underlying biology, as defined by a distinct immunostaining pattern and/or, 
more importantly, by a different clinical outcome. 
 
Since our data derived from supervised and unsupervised analysis of DNA 
copy number profiles showed lack of clear separation of familial and sporadic EOCs 
we sought to determine what other features might characterize the tumors that 
shared a similar genomic instability pattern.  
 
We found that the cluster of EOCs exhibiting greater genomic instability 
(cluster B) was associated with high FIGO stage and serous histological subtype. 
Almost the entire high genomic instability group was composed of serous tumors, of 
mainly high grade, indicating that their copy number profile was substantially 
different from all the other histological types. Noteworthy, all the other histological 
types fell in the cluster of lower genomic instability. This separation mostly coincided 
with the distinction between type I and type II tumors, with the latter ones falling into 
more genomically instable cluster, in agreement with the characteristics of type II 
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tumors that present higher rate of genomic instability,than type I (Kurman & Shih Ie, 
2011b).  
Although  30 different immunohistochmical markers were used only three 
showed to significantly differentiate the groups of tumors defined based on their 
genomic instability profiles. The three markers pointed to greater aggressiveness and 
cellular turnover of the more gnomically unstable tumors.  
Positive staining of TP53 is an indicator of mutated TP53, as the mutations of 
this tumor suppression gene result in a conformational change of the protein, 
stabilizing it and allowing for immunohistochemical detection. More frequent positive 
p53 staining in the tumors from the more genomically unstable cluster is likely to be 
explained by greater enrichment of type II tumors in this cluster, as p53 mutation is a 
specific feature of these tumors (present in more than 80% of the cases)  (Kurman & 
Shih Ie, 2011b). Loss of p53 function allows uncontrolled replication of genetically 
damaged cells, that otherwise would be halted in the p53 proficient cells. This would 
explain the fact that those highly genomically unstable tumors (type II) have 
dysfunctional p53, that allows them to proliferate despite their genomic aberrations 
(Kar et al, 2007; O'Neill et al, 2005).  
Significantly higher Ki-67 expression indicates higher cellular proliferation of those 
more advanced and genomically unstable tumors present in cluster B. The fact that 
the Ki-67 protein is present during all active phases of the cell cycle (G1, S, G2,and 
mitosis), but absent from resting cells (G0), make it an excellent marker for 
determining the growth fraction within tissues (Scholzen & Gerdes, 2000). The other 
significantly associated marker-survivin may be another indicator of high 
proliferative activity of those tumors (Fields et al, 2004) although its main function is 
an inhibition of apoptosis through downstream caspase binding (Altieri, 2003). 
Expression of this marker has not been proved to have an independent predictive or 
prognostic value, however it has been reported to be correlated with other markers 
of unfavorable prognosis like advanced tumor stage, high histological grade, p53 
mutation (Cohen et al, 2003) supporting the finding that more aggressive tumors 
show higher level of genomic instability and a specific pattern of copy number 
changes that can be distinguished from more indolent tumors.     
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6. DELETION AT 6q24-q26 AS AN INDEPENDENT PROGNOSTIC 
MARKER IN OVARIAN CANCER   
 
The tumor groups defined based on their copy number changes did not only 
show some specific immunohistopathological features, but also a significantly 
different outcome. Surprisingly, the cluster of higher genomic instability, a feature 
related to more aggressive tumors (Kurman & Shih Ie, 2011a), showed significant 
association with better overall survival. However, this association could only be 
revealed when factors, known to have an impact on the survival of ovarian cancer 
patients and also found to be significant in our tumor series (such as FIGO stage and 
debulking status) were considered in the model. Since the better survival group was 
enriched in high FIGO stage tumors, this factor was masking the association of the 
tumor group with patients’ survival. That presumption was further confirmed by 
analyzing more homogenous groups composed of high FIGO stage carcinomas alone, 
where the association was observed already at the univariate level, and was further 
shown to be independent of other cofactors. Importantly, since prior reports have 
shown that extreme levels of genomic instability and the presence of mutations in the 
BRCA genes are associated with improved prognosis (Alsop et al, 2012; Baumbusch et 
al, 2013; Birkbak et al, 2011; Bolton et al, 2012) we also considered both variables as 
possible confounders in our analysis. Finally, the examination of distinctive DNA copy 
number changes characterizing the cluster of tumors with better survival led us to 
propose a specific copy number loss at 6q24.2-26 as an independent marker of 
favorable prognosis in ovarian cancer. To define molecular determinants of EOC 
patients’ outcome, previous studies have focused either on single genes (Bacic et al, 
2012; Fujiwara et al, 2012; Kim et al; Madhuri et al, 2012; Quinn et al, 2013) or gene 
expression signatures (Berchuck et al, 2005; Crijns et al, 2009; Konstantinopoulos et 
al, 2010; Sabatier et al, 2009; Spentzos et al, 2004; Verhaak et al, 2013). However, the 
robustness and reproducibility of these new markers/signatures is still questionable 
as they seem difficult to be translated into clinical practice and to overpower well 
established markers such as FIGO stage and debulking status (Yoshida et al, 2009). So 
far very few studies have aimed to identify copy number regions that may predict 
ovarian cancer patients’ outcome (Bruchim et al, 2009; Engler et al, 2012). In 
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addition, none of them led to a definition of a prognostic marker that can be 
implemented into clinics. This could be explained by limited sample sizes, insufficient 
clinical information, use of low resolution platforms or lack of a robust validation.  
 
In this regards we could demonstrate the prognostic value of the 6q24-26 
deletion at the DNA copy number level in a total of 563 tumors and at the gene 
expression level in 1436 EOCs. Furthermore, the deletion proved to be prognostic in 
HGSOCs, the most common and aggressive EOC subtype. Importantly, since its 
prognostic utility was confirmed after further adjustment for BRCA1/2 mutation 
status the association between the 6q24.2-26 loss and an outcome appears to be 
driven by mechanisms other than those proposed to mediate the survival advantage 
of BRCA1/2 mutation carriers (Alsop et al, 2012; Bolton et al, 2012). 
 
The long arm of chromosome 6 is frequently altered in many human 
malignances including leukemias (Burkhardt et al, 2006; Mancini et al, 2005), 
lymphomas (Nelson et al, 2008; Rinaldi et al, 2006; Schwaenen et al, 2009; Tagawa et 
al, 2005), thymomas (Penzel et al, 2003; Rieker et al, 2005),  central nervous system 
neoplasms (Ichimura et al, 2006; Li et al, 2013; Monoranu et al, 2008; Rousseau et al, 
2010; Yin et al, 2009) breast cancer (Chappell et al, 1997; Devilee et al, 1991; Saito et 
al, 2009; Theile et al, 1996), ovarian cancer (Caserta et al, 2008; Foulkes et al, 1993; 
Hansen et al, 2002; Orphanos et al, 1995; Saito et al, 1992; Tibiletti et al, 1996) and 
many others such as melanomas and colon, stomach and liver carcinomas (Carvalho 
et al, 2001; Cui et al, 2011; Guo et al, 2011; Knosel et al, 2003; Vajdic et al, 2003; van 
Gils et al, 2008). The most common alteration of this chromosome is a loss at 6q24-
26, which has been widely studied as a potential location for genes with a tumor 
suppressive role (Hayashi et al, 2012; Stilgenbauer et al, 1999; Sun et al, 2003). 
However, only a few reports have associated this loss with clinical outcome, reaching 
contradictory results, depending on the cancer type. Some of them associated the 
deletion with poor prognosis and tumor recurrence (Cui et al, 2011; Fischer et al, 
2004; Letessier et al, 2007; Schwaenen et al, 2009), while others indicated a favorable 
outcome (Dalsass et al, 2013; Monoranu et al, 2008; Pfister et al, 2009). 
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These discrepancies might be explained by distinct tumor biology and 
treatment strategies. In so far the largest study on EOC by TCGA (TCGA, 2011) the 
only 6q loss defined among the 50 significant focal losses was 6q27, but not 6q24.2-
26. This might be due to different methodology and composition of the tumor series. 
More likely, it may be attributable to the fact that we did not define the 6q24-26 
deletion based on recurrence in HGSOCs, but through comparison of genomic 
aberrations between tumor clusters found to be associated with survival. 
 
7. GENES POTENTIALLY EXPLAINING THE PROGNOSTIC VALUE 
OF 6q24-q26 DELETION  
 
In order to identify a plausible mechanism explaining the association of the 
6q24-26 deletion with improved outcome and to explore its potential clinical 
implications we attempted to define some candidate genes within the region.  
 
We showed that 6q24.2-26 loss has an impact on a gene expression, as 
evidenced by downregulation of 76% genes from the lost region, and a significant 
association of lower mean expression level of all those genes with longer survival. 
Then by multivariate Cox regression analysis we identified several candidate genes 
whose downregulation was significantly associated with better survival.  It is 
noteworthy that despite the fact that 6q24.2-26 loss was associated with survival, and 
the expression of most loci within the region was associated with loss, the expression 
of only few individual genes was associated with an outcome. This might be explained 
by the presence of “passenger” genes at the lost region, whose association with 
survival at the copy number level would result from co-deletion with the “driver/s” 
neighboring gene/s. The analysis of gene expression and survival would account for 
additional mechanisms of down-regulation other than loss (i.e. epigenetic changes, 
mutations) decreasing the confounding effect of physical position and helping to 
pinpoint gene/s likely to drive the survival association.  
 
One of the candidate genes whose expression was significantly associated with 
improved survival was the DNA-binding subunit of SWI/SNF chromatin remodeling 
complex ARID1B. The presence of this gene in the complex is mutually exclusive with 
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ARID1A, which was found to be mutated in clear cell and endometrioid ovarian 
carcinomas (Ayhan et al, 2012; Jones et al, 2010; Wiegand et al, 2010; Xiao et al, 
2012). Although, ARID1A-containing SWI/SNF complexes have been associated with 
tumor suppression (Blais & Dynlacht, 2007; Nagl et al, 2007)  the role of ARID1B-
complexes is not entirely clear. They have been shown to present both a tumor 
suppressive (Khursheed et al, 2013) and pro-proliferative function  (Nagl et al, 2007), 
depending on the context. In addition high expression levels of c-Myc, detected in 
various types of cancers, among them ovarian, are particularly dependent on ARID1B 
(Nagl et al, 2007). All these findings are consistent with improved survival being 
associated with loss of function of ARID1B, as well as for other genes in the region 
with oncogenic properties, such as the TGF-Beta Activated Kinase1/MAP3K7 (TAB2),  
the T-cell lymphoma invasion and metastasis 2 gene (TIAM2) or the Glutamate 
Receptor (GRM1) (Martino et al, 2012; Speyer et al, 2012; Wangari-Talbot et al, 
2012).  
 
Among the genes in the region with oncogenic properties an interesting  
candidate seemed to be ESR1, due its mutagenic role in the response to estrogen 
stimuli and implication of steroid hormones in ovarian cancerogenesis (Ahmad & 
Kumar, 2011). However, we did not find a significant association between its 
expression and survival. Based on the previous evidence on breast cancer, very 
inconsistent and even opposing roles of estrogen have been proposed. Similarly in 
ovarian cancer the evaluation of its prognostic significance has led to conflictive 
results. Some studies reported that ESR1 expression predicts favorable outcome 
(Bizzi et al, 1988; Burges et al, 2010; Halon et al, 2011) while others showed an 
association with worse prognosis (Alonso et al, 2009; Geisler et al, 1996; 
Schlumbrecht et al, 2010). The latest metanalysis including 23 studies focused on the 
role of ESR1 in EOC showed lack of association of ESR1 with patients’ outcome (Zhao 
et al, 2013). 
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Other genes in the regions could be affecting tumor progression in the context 
of treatment. Among them the General Transcription factor IIH Polypeptide 5 
(GTF2H5) that plays an essential role in the nucleotide-excision repair (NER) (Giglia-
Mari et al, 2006; Theil et al, 2013). Given the fact that up to 50% of high-grade EOC 
have a defective HR (TCGA, 2011) compromised expression of genes involved in  
another DNA repair pathway in HR deficient cells might lead to synthetically lethal 
interaction thus enhancing cancer cells’ sensitivity to cytotoxic drugs used to treat 
ovarian cancer  (Chernikova et al, 2012).  If this effect could be demostrated in in vitro 
cytotoxicity assays, GTF2H5 might be used as predictive marker for platinum 
sensitivity in ovarian cancer.  
 
Also in the context of therapy, a recent genome-wide synthetic lethal screen 
for sensitivity to the PARP inhibitor olaparib, revealed that genes that control 
chromatin remodeling and sister chromatic cohesion seem to modulate the response 
to olaparib maybe through DNA-damage repair involvement (Bajrami et al, 2013). 
Based on this findings and given its chromatin remodeling function, impairment of 
the already mentioned ARID1B, might have an alternative implication as predictor of 
response to PARP inhibition and/or to cytotoxic treatment.  
 
Among other candidate genes from the region we have also identified ULPB1, 
one of the NKG2D ligands involved in the immune response. These proteins 
(ULBP1/2/3 and family of RAET1F-M genes) are rarely expressed in normal healthy 
tissues, but are present at high levels in different cancer types and cancer-derived cell 
lines (Coudert & Held, 2006). NKG2D pathway leads to activation of cytotoxic 
lymphocytes and subsequent recruitment of antitumor immune response (Raulet, 
2003), however its involvement varies markedly between different tumors. In 
ovarian cancer high expression of NKG2D ligands- in particular ULBP2 (Li et al, 
2009), RAET1G, RAET1E (McGilvray et al, 2010) have been associated with poor 
prognosis. Although it is not really clear how those immune response molecules 
influence disease progression, it is suggested the high levels of those proteins can 
hinder the infiltration of cytotoxic T lymphocytes and lead to unfavorable outcome by 
allowing tumor cells to escape from immune surveillance.  
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Individual loss of the above mentioned, or of other genes in the deleted region, 
might indeed have an impact on patients’ survival; however, it is also plausible that it 
is not just a single gene that needs to be deleted to influence tumor progression, but 
rather a combination of them. Moreover we should not overlook the role of non-
coding DNA fragments e.g. regulatory elements, miRNAs or specific sequences, as 
some of them have been shown to be essential for maintaining chromosomal 
structure, centromere function or homologous recognition (Subirana & Messeguer, 
2010). 
 
8. CLINICAL RELEVANCE OF 6Q24-Q26 DELETION IN EOC 
 
While the specific genes involved in the association are further delineated and 
the mechanistic determinants are unveiled, the present study has shown that the 
6q24.2-26 deletion is an independent marker of favorable outcome in EOCs.  In 
particular our data indicate prognostic utility in HGSOCs, the most prevalent and 
aggressive EOC histotype. These findings have potentially relevant clinical value as 
this marker could help to guide the selection of patients, whose favorable prognosis 
would support the use of new treatment regimens focused on improving tolerability 
without jeopardizing efficacy. Also, the deletion, together with other emerging 
prognostic and predictive biomarkers in ovarian cancer, could be used to better 
balance patients between treatment arms in clinical trials to reduce the risk of 
confounding. Importantly, DNA-based markers that can be analyzed by FISH, such as 
this deletion, are particularly suitable for routine clinical applications due to their 
robustness and suitability for use with paraffin sections. In addition, the deletion, 
together with other emerging prognostic and predictive biomarkers in ovarian 
cancer, could be used to better balance patients between treatment arms in clinical 
trials to reduce the risk of confounding. Future research in this line should be 
dedicated to the prospective validation of this marker and further characterization of 
tumors that carry the deletion, as well as of the genes in the region. This may not only 
offer insights into tumor biology, but may eventually lead to the development of 
effective targeted therapies.  
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1. Our results indicate that sporadic and familiar EOCs exhibit a similar global pattern of 
DNA copy number changes as reflected by comparable frequency plots and lack of 
stratification by unsupervised hierarchical clustering. Overall, high levels of genomic 
instability and greater contribution of losses versus gains was a common feature in EOCs. 
 
2. We defined a set of recurrent DNA copy number changes shared by sporadic and familial 
EOCs that encompassed known and putative cancer-related genes. These commonly 
altered regions and genes would point to key events in ovarian carcinogenesis in general, 
regardless the existence of germinal mutations in the BRCA1 or BRCA2 genes.  
 
3. Despite general similarity between sporadic and hereditary EOCs, we found that 
extensive genomic loss was significantly higher in tumors from BRCA1 and BRCA2 
mutation carriers. In addition we could also define a few, but potentially specific, BRCA1-
associated alterations. These hallmark features might be clinically relevant as it could 
help to identify BRCA-related patients, who present better prognosis when treated with 
standard regimes and are likely to respond to PARP inhibitors. 
 
4. DNA copy number profiles of BRCAX cases presented the lowest total number of 
alterations overall and in particular of losses resembling more sporadic than BRCA1/2 
tumors.  Also, the greater involvement of losses compared to gains was less marked in 
this tumor group and similar to that observed in sporadic cases, supporting that 
prominent genomic loss is particularly related to BRCA1 and BRCA2 dysfunctions. 
 
5. Groups of EOCs defined based on their DNA copy number profiles showed an association 
with histotype, FIGO stage and proliferation-related markers. In particular we found that 
EOCs of greater genomic instability are more likely to be of higher FIGO stage, serous 
subtype and show increased expression of TP53, Ki-67 and survivin. 
 
6. Deletion at 6q24-q26 was found to be an independent prognostic marker for overall and 
5yrs survival in patients with EOC. In particular, our results indicate prognostic utility in 
high grade serous ovarian carcinomas, the most common and aggressive subtype. This 
marker has a potential clinical value, as it can be analyzed by FISH on tumor sections and 
guide selection of patients towards more conservative therapeutic strategies in order to 
reduce side-effects and to improve quality of life.   
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1. Nuestros resultados indican que los carcinomas epiteliales de ovario (CEO) 
esporádicos y familiares presentan un patrón similar de cambios en el número de 
copias de ADN tal como señalan sus gráficas de frecuencias comparables y la 
ausencia de segregación mediante clasificación jerárquica no supervisada. Un 
rasgo general a todos los CEO fue el alto nivel de inestabilidad genómica y la 
mayor contribución de pérdidas con respecto a ganancias.  
 
 
2. Hemos definido un conjunto de alteraciones en el número de copias de ADN 
comunes entre los CEO esporádicos y familiares que contienen genes ya 
vinculados con la oncogénesis y otros potencialmente relacionados con dicho 
proceso. Estas regiones y genes compartidos apuntarían a cambios cruciales para 
desarrollo del cáncer de ovario independientemente de la presencia de 
mutaciones germinales en los genes BRCA1 o BRCA2. 
 
3. A pesar de la similitud global entre los CEO esporádicos y familiares, la pérdida 
de material genético fue especialmente prominente en los tumores BRCA1 y 
BRCA2.  Además se definió un pequeño número de regiones potencialmente 
asociadas a los tumores BRCA1. Estas características distintivas podrían 
contribuir a la identificación de pacientes “BRCA-like”,  con mejor pronóstico y 
mejor respuesta tanto a la quimioterapia convencional como a los inhibidores de 
PARP.  
 
4. Los tumores BRCAX presentaron el menor número de alteraciones tanto globales 
como de pérdidas, pareciéndose más en ese sentido a los tumores esporádicos 
que a los tumores BRCA1 y BRCA2.  Asimismo la contribución relativa de 
pérdidas en comparación a las ganancias fue menos acusada tal como se observó 
en los tumores esporádicos. Todo ello apoyaría que la abundante pérdida de 
material genético estaría especialmente relacionada con alteraciones en los genes 
BRCA1 y BRCA2.  
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5. Grupos de CEO basados en su patrón de alteraciones en el número de copias de 
ADN mostraron asociación con el subtipo histológico, el estadio FIGO y 
marcadores de proliferación. En concreto observamos que los CEO con mayor 
inestabilidad genómica tendrían más probabilidades de presentar a estadios 
FIGO superiores, ser de subtipo seroso y presentar mayor expresión de TP53, Ki-
67 y survivina. 
 
6. La deleción 6q24-q26 constituiría un marcador pronóstico independiente de 
supervivencia global y a los cinco años en pacientes con CEO. En particular, 
nuestros resultados señalan valor pronóstico en los tumores serosos de alto 
grado, el subtipo más común y agresivo. Este marcador tendría un potencial valor 
clínico ya que puede analizarse mediante FISH en secciones tumorales y guiar la 
selección de pacientes candidatos a recibir tratamientos más conservadores para 
minimizar los efectos secundarios y mejorar la calidad de vida.  
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